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ABSTRACT

Asiago, Josephat M. Ph.D., Purdue University, December, 2014. DJ-1 and
ATP13A2: Two Proteins Involved In Parkinson’s Disease. Major Professor: JeanChristophe Rochet.
Parkinson’s disease (PD) is the second most common neurodegenerative
disorder after Alzheimer’s disease, affecting approximately 0.3% of the total U.S.
population, and its prevalence increases with age. Two neuropathological
hallmarks of PD are the loss of dopaminergic neurons in the substantia nigra
pars compacta, a region in the midbrain involved in initiating and sustaining
movement, and the presence of cytosolic inclusions called Lewy bodies (LBs) in
various brain regions. LBs are enriched with fibrillar forms of the presynaptic
protein α-synuclein (aSyn). Two autosomal recessive genes implicated in familial
PD are PARK9, encoding the P-type ATPase ATP13A2, a lysosomal ATPase;
and PARK7, encoding DJ-1, a protein with proposed antioxidant and chaperone
activities.

Understanding

the

biochemical

mechanisms

underlying

the

neuroprotective functions of DJ-1 and mechanistic details accounting for
functional overlap between ATP13A2 and DJ-1 can provide insight into the
cellular pathways relevant to PD pathogenesis.
DJ-1 belongs to the DJ-1/ThiJ/PfpI superfamily, consisting of proteins that
typically function as proteases and chaperones. Most members of this

xiv
superfamily have shared characteristics including a conserved cysteine residue,
a catalytic triad, and the ability to form oligomers. Whereas PH1704, a bacterial
protease and a member of the DJ-1/ThiJ/PfpI superfamily, adopts a hexameric
structure that is necessary for the formation of a catalytic triad, DJ-1 exists as a
homodimer and apparently has a catalytic diad rather than a catalytic triad. A
recent study has shown that DJ-1Δ15, a truncated form of DJ-1 (15 amino acids
cleaved at the C terminus, resulting in the removal of helix H8, has a much
greater protease activity compared to full length DJ-1. The structure of DJ-1Δ15
is similar to that of PH1704, which lacks a C-terminal helix corresponding to helix
H8 of full-length DJ-1. We chose to focus on DJ-1Δ15 because it was not known
whether this variant has the ability to form a hexamer, or whether such a
hexameric structure is responsible for the observed protease activity (similar to
PH1704). We analyzed DJ-1Δ15 via computer modelling using PyMOL to
determine whether it can form a hexamer with favorable intersubunit interactions.
In addition, we prepared recombinant DJ-1Δ15 and analyzed the protein via
analytical ultra-centrifugation (AUC), native PAGE electrophoresis, and size
exclusion chromatography coupled with multi-angle light scattering. Our PyMOL
results showed that (i) DJ-1Δ15 can from a hexamer which may be stabilized by
two inter-subunit interfaces, referred to as patch 1’ and patch 2 and, (ii) hexamer
formation may lead to the formation of a catalytic triad involving residues C106
and H126 from one subunit and E84 from another subunit. The full length DJ-1
was unable to form the hexamer because helix H8 caused steric hindrances.
Data from AUC and size exclusion analysis of DJ-1Δ15 showed peaks

xv
representing species with different assembly states. There was evidence of a
species with a molecular weight greater than that of the DJ-1Δ15 dimer. In
addition the native gel data of DJ-1Δ15 showed a higher molecular weight
species. Taken together, our results suggest that the DJ-1Δ15 protease activity
may be due to the formation of an oligomer that is larger than the homodimer –
potentially a hexamer.
Analysis of the DJ-1 crystal structure revealed a previously undescribed potential
ATP binding site that included two arginine residues, Arg 28 and Arg 48, near the
oxidizable Cys106 residue. We therefore focused on elucidating whether DJ-1
binds and hydrolyzes ATP. We found that our preparations of recombinant,
human WT DJ-1 had ATPase activity that was lost upon filtration or
ultracentrifugation. Analysis of our protein samples via sucrose gradient
sedimentation coupled with immunoblotting revealed the presence of high
molecular weight (high-MW) species immunoreactive with a DJ-1 antibody in our
DJ-1 preparations. Additional studies revealed that the high-MW protein fraction
of our DJ-1 preparations had ATPase activity and consisted of ring-like structures
that could be visualized by electron microscopy. Furthermore, a DJ-1-positive
high-MW complex isolated from these preparations by sucrose gradient
sedimentation was shown via mass spectrometry analysis to contain F 1 ATPase
subunits, which are also known to assemble into ring-like structures, suggesting
that the ATPase activity in our high molecular weight fraction might be associated
with assembled F1 ATPase. Consistent with this idea, the ATPase activity in our
high molecular weight protein fraction was abolished in the presence of sodium

xvi
azide or piceatannol, classical F1 ATPase inhibitors. Furthermore, we obtained
evidence that dimeric DJ-1 may interact with purified E-coli F1 ATP synthase, and
this interaction was apparently dependent on the presence of a reduced cysteine
residue at position 106. These results imply that (i) F1 ATP synthase (in
mitochondria) may be a target of the DJ-1 chaperone activity, and (ii) this
interaction may be modulated by DJ-1 oxidation.

Loss-of-function mutations in the ATP13A2 or DJ-1 gene have been shown to
disrupt lysosomal autophagy and interfere with mitochondrial function and quality
control. We hypothesized that dysfunction of either protein elicits neurotoxicity by
triggering defects in autophagy coupled with an accumulation of dysfunctional
mitochondria. To address this hypothesis, we investigated the functional interplay
between ATP13A2 and DJ-1 in terms of their ability to protect neuronal cells
against a PD related stress, methamphetamine (METH), an abused drug that
disrupts autophagy in N27 dopaminergic neuronal cells. Our results showed that
knocking down ATP13A2 or DJ-1 results in a buildup of LC3 II, an autophagic
marker, whereas ATP13A2 over-expression reduces the accumulation of
autophagic vesicles, termed autophagosomes. In addition, ATP13A2 or DJ-1 KD
N27 cells showed a decreased rate of O2 consumption. Strikingly, the level of
ATP13A2 mRNA was increased in DJ-1 knockdown in primary midbrain cultures;
in contrast the level of DJ-1 mRNA was decreased in ATP13A2 knockdown in the
same cultures. These results suggest DJ-1 and ATP13A2 interact functionally in
regulating lysosomal degradation and mitochondrial function.

xvii
Overall, these studies have yielded insights into biochemical mechanisms of DJ1-mediated neuroprotection and of the functional interplay between DJ-1 and
ATP13A2. Not only do these findings advance our understanding of
neuroprotective mechanisms relevant to PD, but they also suggest new
strategies to treat this devastating syndrome.

1

CHAPTER 1: INTRODUCTION

1.1. Parkinson’s disease: an irreversible, progressive, neurodegenerative
disease
Parkinson’s disease (PD) is an irreversible neurodegenerative disease that was
discovered in 1817 by a scientist named Dr. James Parkinson. In his “essay on
shaking palsy”, Dr. Parkinson described the disease as characterized by
involuntary tremulous movement and decreased muscular power[1]. Two
neuropathological hallmark of PD is the loss of dopaminergic neurons in
substantia nigra pars compacta, a region in the brain involved in initiating and
sustaining movement and, the presence of cytosolic inclusions called Lewy
bodies (LBs) in various brain regions [2, 3]. PD is the second most common
neurodegenerative disease affecting approximately 0.3% of the total U.S.
population and its prevalence increases with age, affecting up to 2% of the
population over 65 years [4] and 5% of the population over 85 years old [5]. The
U.S. government spent over $14 billion on persons with PD in 2010 [6]. It is
estimated that the number of people suffering from PD is likely to double by 2040
[6], and, concurrently, the cost of diagnosis and treatment will continue to rise.
With the increase in lifespan due to improved health care, there is a need to
understand the disease etiology at the molecular level and develop alternative
therapies. The research described herein will provide insight into PD
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pathogenesis by analyzing two PD related recessive gene products, DJ-1 and
ATP13A2.
1.2.

Symptoms, pathology, diagnosis and treatment of PD
1.2.1. Symptoms and pathology

Dr. James Parkinson designated the clinical symptoms of PD as difficulty
initiating movements, resting tremor and rigidity [1]. Besides the typical
parkinsonian motor dysfunction, PD patients present non-motor symptoms
(NMS) including neuropsychiatric, sensory, autonomic, and sleep disorders [7].
These symptoms can lead to disability and a poor quality of life [8, 9]. Two
neuropathological hallmark of PD are the loss of dopaminergic neurons in
substantia nigra pars compacta (SNc), a region in the brain involved in initiating
and sustaining movement and, the presence of cytosolic inclusions called Lewy
bodies (LBs) [2, 3]. LB have been observed in different regions of the brain,
including locus coeruleus, dorsal vagal, nucleus and anterior cingulate gyrus [10].
LBs are granular or globular inclusions present in the soma of affected neurons.
Lewy neurites are diseased neurons containing granular material majorly aSyn
filaments. PD progression is classified into 6 stages based on the regions of the
brain affected by Lewy neurites and LBs [11]. Stage 1-2, medulla and pons,
stage 3, substantia nigra (SN), stages 4-6, hippocampus and neocortex [11]. LBs
are mainly composed of fibrillar forms of the presynaptic protein, aSyn [12-14].
1.2.2.

Diagnosis and treatment of PD

The presence of LBs at autopsy is considered a confirmatory of a PD diagnosis
[15]. Other diagnoses are based on the typical loss of motor functions, NMS, and
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response to levodopa [16]. Levodopa (L-DOPA) is a drug that slows down PD
pathogenesis

by

controlling

PD

motor

related

symptoms,

particularly

bradykinesia [17]. L-DOPA penetrates the central nervous system via the blood
brain barrier where it is converted to dopamine via decarboxylation by aromatic
amino acid decarboxylase (AADC) [18]
Other alternatives in the management of PD include catechol-o-methyltransferase

(COMT)

inhibitors,

dopamine

receptor

agonists

and

non-

dopaminergic therapy (for example adenosine A2A antagonists) which may be
used in conjunction with levodopa [19]. The above mentioned PD management
therapies generally lose their therapeutic efficacy over time. Some of the
reported side effects include recurrence of motor symptoms and dyskinesia [20].
In addition, although surgical intervention of patients with motor dysfunction, (e.g.
via deep brain stimulation (DBS)) can have many benefits, it is costly and can
cause complications such as infections [21].

None of the aforementioned

therapies halts the underlying neurodegeneration, therefore there is a need to
develop alternative strategies. Understanding cellular mechanisms that slow
neurodegeneration in the brains of PD patients may suggest new therapeutic
strategies.
1.3. Idiopathic PD
PD can be classified into two categories: (i) idiopathic PD, also known as
sporadic PD; and (ii) familial PD. Idiopathic PD accounts for 90-95% of all PD
cases and is caused by non-genetic factors that include aging (the greatest risk
factor), exposure to herbicides or pesticides or organic solvents, industrialization,
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living in a rural environment, and drinking well water [22-24]. A number of toxic
mechanisms have been proposed to play a role in PD pathogenesis, including
mitochondrial dysfunction, oxidative stress, and accumulation of misfolded
protein and damaged organelles due to dysregulation of proteasomal and
lysosomal degradation pathways [25-28]. The focus of this thesis is on the role of
mitochondrial

dysfunction

and

dysregulation

of

lysosomal

degradation

(autophagy).
1.3.1.

Mitochondrial dysfunction and oxidative stress

Analysis of the SNc and frontal cortex regions of post-mortem PD brains shows a
decreased activity of complex I, an enzyme of the mitochondria electron transport
chain [29-31]. In addition complex I subunits in PD brains show evidence of
increased oxidative damage as a result of accumulation of protein carbonyls [32].
Complex I inhibition decreases mitochondrial adenosine triphosphate (ATP) and
may cause a ‘leakage’ of electrons from the electron transport chain, leading to
formation of reactive oxygen species (ROS), that damage mitochondrial DNA (mt
DNA) and cause further mitochondrial impairment [33-35]. Oxidative stress
occurs under conditions that lead to an imbalance between ROS production and
antioxidant activity [22]. Dopaminergic neurons contain high level of ROS due to
the presence of dopamine. Similar to other catecholamines, dopamine
undergoes auto-oxidation to form the o-quinone form (Fig 1.1), a reaction that
involves the generation of superoxide radicals [36]. In addition, dopamine readily
is metabolized by tyrosinase and monoamine oxidase, two ROS-generating
enzymes [18, 22]. Free radicals formed as a result of dopamine auto-oxidation or
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metabolism can damage mitochondrial electron transport subunits, thereby
leading to further oxidative stress associated with mitochondrial dysfunction as
part of a vicious cycle [37]. Because dopaminergic neurons have higher basal
levels of oxidative stress than other types of neurons, they are more susceptible
to pathogenic mechanism that further up-regulate ROS, including mitochondrial
dysfunction. ROS are thought to elicit toxicity through oxidative modification of
macromolecules and organelles [38-40]. As one example, ROS cause lysosomal
destabilization, by disrupting membrane integrity, a process referred to as
lysosomal membrane permeabilization (LMP).
1.3.2.

Lysosomal involvement in PD

Lysosomes are involved in the clearance of long-lived proteins, including
aggregated forms of aSyn, and the removal of old or dysfunctional organelles
like mitochondria [41, 42]. Previous studies have shown impaired lysosomal
clearance in dopaminergic neurons in both sporadic and genetic PD patients,
suggesting that lysosomal impairment may contribute to pathogenesis of PD [43]
[44]. Mutations in lysosomal proteins such as glucocerebrosidase (GBA) and
ATP13A2, a lysosomal ATPase are associated with PD [45]. These findings
suggest that restoring lysosomal function could be a reasonable therapy for PD.
1.3.3.

Autophagy in PD

Autophagy has been referred to classically as a process induced in cells to
enable the degradation of intracellular components under starvation conditions
[46, 47]. There are three types of mammalian autophagy: (i) microautophagy, a
process by which the lysosomal membrane surrounds and engulfs cytoplasmic
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components for degradation; (ii) chaperone mediated autophagy (CMA),
involving the targeting of proteins with a specific sequence motif for uptake into
lysosomes with the assistance of the molecular chaperone, Hsc70 [48]; and (iii)
macroautophagy (referred to herein as ‘autophagy’), a multi-step process that
involves the sequestration of organelles and cytoplasmic components via the
formation of a double-membrane-bound organelle called an autophagosome [48,
49]. Autophagosomes fuse with lysosomes to form autolysosomes, wherein the
intra-lumenal components are degraded by lysosomal hydrolases [50] (Fig. 1.2).
In mammalian cells, the microtubule associated protein light chain 3 (LC3) is
modified via a ubiquitylation-like system [51, 52] to form LC3-I and LC3-II. LC3-I
is a soluble form generated upon carboxyl terminal cleavage of pro-LC3 [53, 54].
LC3-I is modified to a membrane-bound form, LC3-II, by conjugation to
phosphatidylethanolamine

[54,

55].

Importantly,

LC3-II

localizes

to

the

autophagosome and autolysosomes and is thus a characteristic marker of these
vesicular structures [56] (Fig. 1.2).

Defects in autophagy are associated with

various diseases including PD [47]. Aggregated proteins and dysfunctional
organelles that cannot be degraded via the ubiquitin-proteasome pathway are
cleared from the cell via lysosomal autophagy [57]. Accordingly, dysregulation of
autophagy leads to the accumulation of protein aggregates and dysfunctional
organelles in PD [58].
1.4. Familial PD
To date, there are 28 distinct chromosomal regions that have been identified as
being related to familial PD or parkinsonism [59]. Familial PD cases account for
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5 % of total PD cases. Eighteen specific chromosomal loci, (referred to as PARK
loci) have been identified. These loci are classified chronologically (PARK 1-18)
(Table 1.1) depending on when they were identified [59].
1.4.1. Alpha-synuclein (PARK1, 4)
1.4.1.1. Genetics
As mentioned above, aSyn is a major component of Lewy pathology in patients
with sporadic form of PD [14]. Missense mutations in the aSyn gene have been
linked to familial PD. The following familial substitutions have been identified;
alanine to threonine at residue 53 (A53T) [60], alanine to proline at residue 30
(A30P) [61], glutamate to lysine at residue 46 (E46K) [62], histidine to glutamine
at residue 50 (H50Q) [63], glycine to aspartate at residue 51 (G51D) [64] (Fig
1.3). Duplication and triplication mutations increase the copy number of the wild
type aSyn gene [65, 66]. Although some substitution mutants e.g. A53T form
fibrils more rapidly than wild type aSyn, overall the neurotoxic effects of familial
PD mutants appears to result from the formation of protofibrils rather than
accelerated fibrillization [67]. Some of the substitution mutants appear to favor
oligomerization though not necessarily fibril formation [63, 64] Duplication and
triplication mutations favor aggregation of the protein via mass action [68]. In
addition there is an increased level of cytoplasmic aSyn in aging human brain
[69].

8
1.4.1.2. aSyn function
aSyn is a 140 amino acid protein that localizes to presynaptic terminals [70]. The
aSyn sequence is subdivided into three domains: (i) an N-terminal domain
(residues 1-67), consisting of seven imperfect repeats, six of which contain the
conserved hexamer sequence KTK(E/Q)GV (Fig 1.3), this conserved sequence
plays a critical role in the association of aSyn with phospholipid membranes [71,
72]; (ii)

the non-amyloid-β-component of Alzheimer’s disease (NAC) domain

(residues 61-95), consisting primarily of hydrophobic residues that initiate
aggregation [73]; and (iii) the carboxy-terminal (C-terminal) region (residues 96140), enriched with negatively charged residues (aspartate, glutamate) and
proline residues (Fig 1.3). Truncation of C-terminal accelerates rates of
aggregation [74-76], and truncated forms of aSyn are present in LBs [77].
In addition, aSyn may be involved in regulating synaptic vesicle release [78-80],
and the protein modulates synaptic transmission [81-83], dopamine (DA) uptake
[84, 85], and assembly of the SNARE complex [86].
1.4.1.3 aSyn degradation in PD
Abnormal aSyn expression causes defects in cellular protein degradation
pathways [42]. The ubiquitin-proteasome system (UPS) [87-90] and lysosomal
autophagy [91-94] are involved in the degradation of aSyn. Phosphorylated aSyn
(pS129) has been shown to be degraded via the proteasome [95, 96]. In addition,
in vivo studies have shown that at high expression levels aSyn is cleared via
macroautophagy in transgenic mouse brains, whereas at lower expression, (i.e.
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nontransgenic mouse) aSyn is eliminated via proteasomal degradation [97]. In
contrast, other studies have reported that overexpression of aSyn disrupts
macroautophagy [98]. Accordingly, disruption of the UPS and lysosomal
autophagy is predicted to cause accumulation of aSyn, leading to the formation
of toxic aSyn oligomeric species involved in neurodegeneration. Targeting
degradation pathways may be a reasonable therapeutic strategy for PD.
1.4.2.

DJ-1 (PARK7)

1.4.2.1. Genetics
Deletions and point mutations resulting in a loss of functional DJ-1 protein are
involved in autosomal recessive PD [99]. A six exon deletion has been reported
in a Dutch family, and a missense mutation resulting in the substitution of proline
for leucine at residue 166 (L166P) has been found in an Italian family [99].
Additional homozygous recessive, substitution mutations include M26I [100],
E64D [101], E163K [102], A104T [103]. Other studies revealed a mutation in the
DJ-1 promoter [102]. In addition, two polymorphisms encoding the substitutions
R98Q [103] D149A [100], have been identified in the DJ-1 gene.
1.4.2.2. Protein structure
DJ-1 is a protein composed of 189 amino acids that is encoded by the PARK7
gene. Data from gel filtration, sedimentation and x-ray crystallographic analysis
indicate that purified recombinant DJ-1 exists as a homodimer [104-108].
Monomeric DJ-1 has eight alpha helices and eleven beta strands [107] (Fig 1.4).
DJ-1 belongs to the ThiJ/PfpI family, consisting of proteins that typically function
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as proteases and chaperones [109], and its amino-acid sequence is conserved
among many species [110, 111]. Shared features of proteins in this superfamily
include a conserved cysteine residue in a “nucleophile elbow” strand-loop-helix
motif [106], a catalytic triad (cysteine, histidine and glutamate/aspartic acid) in
some (but not all) members, and the ability to form oligomers [106]. The
oligomeric state of these proteins varies widely ranging from dimers to hexamers
[106].
The structure of the monomeric subunit of DJ-1 is highly homologous to that of
the monomeric subunit of PH 1704, an intracellular cysteine protease from
Pyrococcus horikishii, forms a hexamer stabilized by two types of inter-subunit
interfaces, referred to as patch 1’ and patch 2 [105, 112, 113]. Patch 1’ is
analogous to the interface between the two monomeric subunits of homodimeric
DJ-1 (referred to as patch 1), although the two interfaces are rotated ~90°with
respect to each other. The structural features that lead to the presence of a patch
1 interface in the DJ-1 dimer but a patch 1’ interface in the PH1704 hexamer are
poorly understood.
1.4.2.3. Functions of DJ-1
Since its initial discovery as an oncogene [114], DJ-1 has been reported to have
many other functions (reviewed in [115, 116] ). Here we review functions of DJ-1
related to its ability to act as an antioxidant, molecular chaperone, transcriptional
regulator, modulator of mitochondrial function, modulator of autophagy and a
protease.
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1.4.2.4. Antioxidant function of DJ-1
Rotenone and 6-hydroxydopamine (6-OHDA), two known PD-related oxidative
stressors, have been shown to up-regulate endogenous DJ-1 mRNA and protein
levels and to induce translocation from the cytoplasm to mitochondria [117].
Oxidation of a cysteine residue at position 106 (C106) to the sulfinic acid (SO 2H)
facilitates translocation of DJ-1 from the cytoplasm to mitochondria [118-120].
Oxidized DJ-1 enhances cell proliferation by binding and inhibiting apoptosis
signal-regulating kinase (ASK1) [121, 122]. Over expression of wild type DJ-1,
but not familial mutant forms of the protein, protects neuronal cells from reactive
oxygen species (ROS) [123], whereas down-regulation of DJ-1 sensitizes cells to
oxidative stress [124]. DJ-1 protects against toxicity elicited by hydrogen
peroxide (H2O2), 6-OHDA and rotenone by up-regulating the antioxidant
molecule glutathione, whereas it induces an increase in levels of the heat shock
protein 70 (HSP 70) in neuronal cultures expressing mutant aSyn [125, 126].
These results suggest that DJ-1 protects against various PD-related insults, and
the mechanism of DJ-1 neuroprotection depends on the type of stress.
1.4.2.5. A role for DJ-1 as at transcription regulator
Under conditions of oxidative stress, DJ-1 has been found to regulate various
genes at the transcriptional level [125, 127]. DJ-1 knockdown in the mouse
NIH3T3 cell lines induce a decrease in the level of extracellular superoxide
dismutase (SOD3), an enzyme that scavenges ROS [127]. DJ-1 regulates
cholesterol synthesis by activating on the promoter region of the low-density
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lipoprotein receptor (LDLR) gene [128]. In the cells exposed to oxidative stress,
DJ-1 forms a complex with the sterol regulatory binding protein 2 (SREBP2), a
transcription factor involved in cholesterol synthesis, and binds to the sterol
regulating element (SRE) to stimulate the LDLR promoter activity [128]. DJ-1
positively regulates of the androgen receptor (AR) transcription factor through
binding to the same promoter region as PIAS-alpha, a repressor that inhibits
androgen receptor transcription activity [129, 130]. Studies in yeast have shown
that DJ-1 can directly bind to AR [131]. In addition, DJ-1 stabilizes nuclear factor
(erythroid-derived 2)-like 2 (Nrf2), a redox-sensitive transcription factor that
regulates the expression of antioxidant and detoxifying genes in response to
oxidative stress via the antioxidant response element (ARE) [132]. Although DJ-1
averts the formation of a complex between Nrf2 and Kelch-like erythroid cellderived protein-1 (Keap1), a negative regulator of Nrf2 [133], there is currently no
evidence that DJ-1 binds directly to Nrf2 or Keap1, and thus the mechanism by
which DJ-1 stabilizes Nrf2 has yet to be elucidated [134]. In contrast, other
studies have reported that Nrf2-ARE is activated in DJ-1 knock out (KO) mice
[135]. Two more transcription factors regulated by DJ-1 are p53 and nuclear
factor-кβ (NF-кB). p53 is involved in many cellular functions including apoptosis
and the maintenance of mitochondrial homeostasis during oxidative stress [136].
DJ-1 has been reported to be both a positive regulator of p53 [136] and an
inhibitor of p53 transcriptional activity under normal conditions [137] and
conditions of oxidative stress [138]. Interactions between DJ-1 and Cezanne, an
inhibitor of the transcriptional activity of NF-кB, allow for the activation of NF-кB.
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NF-кB is involvement in many cellular roles including cell survival [139] and the
regulation autophagy [140]. These studies suggest that DJ-1 is an upstream
regulator of various transcription factors.
1.4.2.6. A role for DJ-1 as a redox-sensitive molecular chaperone
The structures of DJ-1 and HSP 31, an Escherichia coli chaperone that is a
member of the DJ-1/ThiJ/PfpI superfamily, are conserved [108]. Analysis of the
DJ-1 crystal structure revealed hydrophobic patches with the necessary chemical
and geometric features to bind non-native protein substrates [108]. DJ-1 acts as
a redox-dependent molecular chaperone that inhibits aSyn oligomerization and
fibrillization [141, 142]. One group reported that mutation of cysteine 53
abrogates a low isoelectric point variant of the protein and abolishes the
chaperone and protective function of DJ-1 [141]. In addition, two separate groups
have reported that cysteine 106 oxidation is critical for DJ-1 to function as a
chaperone against aSyn misfolding [142, 143].

Furthermore, DJ-1 has been

reported to impede the aggregation of citrate synthase (CS) and luciferase [108].
1.4.2.7. Role of DJ-1 in regulating mitochondrial homeostasis
Mitochondrial dysfunction and oxidative damage are characteristic features of
neurodegenerative diseases, including PD [144]. Mutations in genes directly
linked to mitochondrial function, i.e. Parkin, PINK1, and DJ-1, have been
identified in familial forms of PD [144]. Parkin is an E2-dependent E3 ubiquitin
ligase [145, 146], plays a role in bioenergetics and mitochondrial quality control
pathways [147]. Notably, Parkin is recruited to depolarized mitochondria to
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enhance its elimination by autophagy and regulates the levels of PGC-1α, an
important regulator of mitochondrial biogenesis [148, 149].

PINK1 (PTEN-

induced putative kinase 1) regulates mitochondrial homeostasis via HtrA2, a
mitochondrial protease [150], regulates mitochondrial morphology in mammalian
cells [151], and plays a role in recruiting Parkin to mitochondria of immortalized
cells [152-154]. Loss or mutation of DJ-1 induces an increase in ROS levels, a
decrease in respiration rates and mitochondrial membrane potential (MMP), and
a disruption of the critical balance between mitochondrial fusion and fission [144].
Oxidative stress in M17 human neuroblastoma cells results in DJ-1 relocalization to mitochondria, a phenomenon associated with protection against
cytotoxicity [117, 118]. DJ-1 has also been shown to protect neurons from
rotenone-induced oxidative stress and cell death [155-157]. Mitochondrial defects
caused by deficiency or mutation of these three genes can be rescued by trio of
the

enzymes

[158].

Mitochondrial

fragmentation

triggered

by

aSyn

overexpression can be rescued by overexpression of wild-type Parkin, PINK1, or
DJ-1, but not their functionally deficient mutants [159]. Recruitment of Parkin to
depolarized mitochondria is influenced by oxidative stress of wild-type DJ-1 and
not its mutant, C106A [160]. Elucidating the structure and function of this trio of
enzymes will provide new avenues for developing therapies in PD.
1.4.2.8. Role of DJ-1 as a protease
As mentioned above, the Pyrococcus horikoshii 1704 gene product PH1704
exists as a hexamer [53]. This quaternary structure is thought to be essential for
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the assembly of a catalytic triad at one of the subunit interfaces (referred to as
patch 2 above). DJ-1 has an additional α helix (helix H8) at the C-terminus
compared to PH1704. A recent study has shown that a truncated form of DJ-1
(15 amino acids cleaved at the C terminus, resulting in the removal of helix H8)
has much greater protease activity compared to full length DJ-1 [46]. In this study
DJ-1 was proposed to act as a cysteine protease with C106 and H126 forming a
catalytic diad. The C-terminally truncated form of DJ-1 (DJ-1Δ15) was found to
accumulate in dopaminergic cells exposed to oxidative stress, leading to
conclude that full-length WT DJ-1 is in fact a zymogen that becomes activated
via a redox-sensitive mechanism [46].
1.4.2.9. Impact of DJ-1 on lysosomal function
Cells lacking DJ-1 exhibit an increase in dysfunctional mitochondria and
mitochondria-derived ROS [144]. In turn, ROS accumulation can induce
permeabilization of lysosomal membranes thereby leading to impaired
autophagic clearance and recycling of cytoplasmic constituents, termed basal
autophagy [144, 161]. DJ-1 is thought to indirectly regulate autophagy through
the extracellular signal regulated protein kinase 1/2 (ERK1/2), a kinase involved
in stimulating lysosomal degradation and inducing autophagy [144, 162]. A
disruption in the autophagic mitochondrial clearance (mitophagy) results in a
build-up of defective mitochondria. Accordingly, a loss of DJ-1 activity leads to a
vicious cycle of mitochondrial dysfunction and defects in lysosomal autophagy.
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1.4.3. ATP13A2 (PARK 9)
1.4.3.1. Genetics
ATP13A2 is a P type ATPase encoded by the PARK 9 gene. It is located at
chromosome 1p36 between two other PARK loci, PARK6 and PARK7 [163, 164].
ATP13A2 is a 1,180-residue protein that contains ten transmembrane spanning
helices [165] and is hypothesized to be localized to the lysosome.

P-type

ATPases are characterized by their ability to undergo large conformational
changes while pumping ions across biological membranes via a process
involving ATP hydrolysis. Mutations in the PARK9 gene result in autosomal
recessive PD, suggesting a role for the lysosome in neurodegeneration [166,
167]. There are three genetic lesions that have been identified at this locus: (i)
heterozygous mutations leading to truncation or in-frame deletion, identified in
patients with Kufor-Rakeb syndrome, (KRS) [164]; (ii) a homozygous mutation
encoding the substitution G504R [168]; and (iii) heterozygous mutations
encoding T12M and G533R[168].
1.4.3.2. Expression and localization
ATP13A2 is mainly expressed in the dopaminergic neurons of the substantia
nigra in the brain [164]. Other studies have reported that ATP13A2 expression
peaks during neurogenesis [169]. Hypoxic conditions increase the transcription of
ATP13A2, in HEK 293 and MN9D, dopaminergic cells [170]. Furthermore, high
levels of manganese (II) and Zinc elevates expression of ATP13A2 [171, 172].
ATP13A2 is hypothesized to be localized to the late endosomes and lysosomes.
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There are three ATP13A2 splice variants [173]. Variant 3 is retained in the
endoplasmic reticulum (ER) where it is rapidly degraded [173]. ATP13A2 has
recently been reported to localize to the outer membrane of amphisomes [174].
1.4.3.3. Protein structure
There are three alternatively spliced ATP13A2 isoforms expressed in humans
[173]. Isoform 1 encodes a protein with 1180 amino acids consisting of 10
transmembrane domains. Isoform 2 encodes a protein of 1175 amino acids
[173]. The loss of 5 residues in isoform 2 compared to isoform 1 is the results of
an in-frame deletion near the N-terminus [173]. Isoform 3 encodes a protein with
1158 amino acids; compared to isoform 1, this variant has an in-frame deletion of
117 bases, generating a highly diverse C-terminus [173]. My study will focus on
isoform-1 of ATP13A2.
1.4.3.4. Protein function
1.4.3.4.1. Role of ATP13A2 in autophagy and mitochondrial clearance
ATP13A2 is involved in the ATP-dependent transport of cations across lysosomal
membranes [164]. The localization of ATP13A2 to lysosomal membranes may
play a key role in modulating autophagy. A loss of ATP13A2 function has been
shown to compromise lysosomal acidification, decrease proteolytic processing of
lysosomal enzymes, and reduce the degradation of lysosomal substrates [175].
Because dysfunctional mitochondria are degraded via autophagy [144],
impairment of autophagy resulting from ATP13A2 depletion is thought to trigger a
buildup of defective mitochondria that produce increased ROS [144, 176].
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Expression of ATP13A2 protects mammalian cells from oxidative stress and
dysfunctional mitochondria [177]. In addition, loss of ATP13A2 function in human
fibroblast decreases ATP production rates, mitochondrial DNA lesions, increased
maximum respiration and mitochondrial fragmentation [178]. Previous studies
have shown that the yeast homolog of human ATP13A2 suppresses aSyn
toxicity in yeast and that it can also protect yeast cells from manganese toxicity
[179, 180]. These studies suggest a relationship between genetics and the
environment as the cause of neurodegeneration [179]. ATP13A2 regulates
lysosomal functions and thus suggesting that it might control lysosomal aSyn
degradation and buildup of aSyn aggregation [175, 181, 182]. ATP13A2 is
involved in trafficking aSyn to the lysosome via macro-autophagy [175, 181].
Other studies have reported that ATP13A2 enhances removal of aSyn from the
cell via exosomes [174].
1.4.3.4.2. Role of ATP13A2 in aSyn clearance
ATP13A2 has been reported to protect both yeast and mammalian cells against
aSyn toxicity [179]. ATP13A2 may control aSyn degradation via lysosomal
macroautophagy, thus preventing the accumulation of aSyn aggregates [175,
181, 182]. Overexpression of ATP13A2 protects cells from mitochondrial
fragmentation induced by aSyn [176, 178, 183]. In addition, ATP13A2 enhances
the elimination of aSyn out of the cell via an exosome-mediated pathway [174].
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1.4.3.4.3. P-type ATPase Ion transporter
ATP13A2 shares sequence homology with P-type ATPases, a large family of ion
pumps that utilizes ATP to transport ions across membranes in eukaryotes and
prokaryotes [164] (Table 1.2). P-type ATPases are characterized by their ability
to undergo large conformational changes while pumping ions across biological
membranes via a process involving ATP hydrolysis. P-type ATPase is classified
into five subfamilies; ATP13A2 is a type-5- P type ATPase, a sub family of Ptype ATPase expressed only in eukaryotes. Although ATP13A2 is homologous to
members of the P-type ATPase family, its ion specificity and biological function
are unknown (Table 1.2). Dysfunction of ATP13A2 may lead to accumulation of
misfolded or damaged polypeptides.
1.5 Objectives of this thesis
The above sections highlight advances in our understanding of DJ-1 and
ATP13A2 neuroprotective activities. However, a number of key questions about
the function of these two proteins remain unanswered: (i) what are biochemical
mechanisms underlying the neuroprotective function of DJ-1? (ii) How does DJ-1
suppress mitochondrial dysfunction? (iii) Do DJ-1 and ATP13A2 interact on a
functional level to modulate mitochondrial and lysosomal function?
This thesis addresses these questions by studying the formation of high-order
oligomers by a C-terminally truncated form of DJ-1 in a cell-free system. We also
explore a potential mechanism for DJ-1 protective effects against mitochondrial
dysfunction through the characterization of an interaction between DJ-1 and E.
coli F1 ATPase, an enzyme that is highly conserved relative to F1 ATPase in
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mammalian mitochondria. Lastly, we examine the interplay between DJ-1 and
ATP13A2 in modulating mitochondrial and lysosomal functions in neuronal cells
exposed to PD-related insults. These studies will provide insight into molecular
phenomena underlying PD pathogenesis, and they may suggest new
neuroprotective strategies.
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Oxidation

Figure 1.1 Dopamine undergoes auto-oxidation to form dopamine o-quinone
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Hydrolase

LC3 II

Cytoplasmic
protein and
organelles
Lysosome

Isolated

Phagophore

Autophagosome

Autolysosome
Figure 1.2 Macroautophagy
Macroautophagy starts by the formation of a cup-shaped isolated double membrane that engulfs
cytoplasmic protein and organelles. LC3 II (an autophagic marker), is bound to the membrane of
the phagophore and autophagosomes and is present in autolysosomes that result from
autophagosome-lysosome fusion. The cytoplasmic proteins and organelles are degraded by
lysosomal hydrolases.
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Figure 1.3 The domain and amino acid sequence of human WT aSyn.
(A) aSyn contains 140 amino acids composed of three regions: (i) the amphipathic N-terminal region
spanning residues 1-67, (ii) the hydrophobic NAC region, spanning residues 61-95, and (iii) the acidic Cterminal region, spanning residues 96-140. Six of the imperfect repeats contain the conserved hexamer
sequence KTK(E/Q)GV (boxed region). The arrows point to the familial mutants. (B) Amino acid sequence
of human WT aSyn. Familial mutants are indicated by blue asterixes. Adapted from Dr. Strathearn’s
(former lab member) thesis.
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Figure 1.4 Structural model of the human DJ-1 homodimer. The structure was generated
via PyMOL.
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Table 1.1 Familial PD-related genes. AD, Autosomal dominant; AR, Autosomal
recessive.

Symbol

Gene Locus

Gene

Inheritance

PARK1

4q21-22

aSyn

AD

PARK 2

6q25.2-q27

Parkin

AR

PARK 3

2p13

Unknown

AD

PARK 4

4q21-q23

aSyn/triplication

AD

PARK 5

4p23

UHCL1

AD

PARK 6

1p35-p36

PINK1

AR

PARK 7

1p36

DJ-1

AR

PARK 8

12q12

LRRK2

AD

PARK 9

1p36

ATP13A2

AR

PARK 10

1p32

Unknown

Risk factor

PARK 11

2q36-27

Unknown

AD

PARK 12

Xq21-225

Unknown

Risk factor

PARK 13

2p12

HTRA2

AD/Risk factor

PARK 14

22q13.1

PLA2G6

AR

PARK 15

22q12-q13

FBX07

AR

PARK 16

1p32

Unknown

Risk factor

PARK 17

16q11.2

VPS35

AD

PARK 18

3p27.1

EIF4G1

AD
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Table 1.2 A list of the P-type ATPase’s
P-

Gene

Substrate

Disorder

ATP7A

Cu2+

Menkes disease (MD), Occipital horn Syndrome

type
P1B

(OHS), Spinal muscular atrophy, distal, X-linked 3
(SMAX3)
P1B

ATP7B

CU2+

Wilson disease (WD), Possible genetic risk factor
for Alzheimer’s disease (AD)and
parkinsonism

P2B

ATP2B3

Ca2+

Early onset X-linked spinocerebellarataxia1

P2C

ATP1A2

Na+/K+

Familial hemiplegic migraine type2(FHM2),
Alternating hemiplegia of childhood1(AHC1)

P2C

ATP1A3

Na+/K+

Rapid-onset dystonia parkinsonism (DYT12,RDP)
Alternating hemiplegia of childhood 2 (AHC2)

P4

ATP8A2

PS

Cerebellar ataxia, mental retardation and
disequilibrium syndrome 4 (CAMRQ4)

P4

ATP10A2 ?

Angelman syndrome (AS)

P5B

ATP13A2 ?

Kufor-Rakeb syndrome (KRS)
Neuronal ceroid lipofuscinosis (NCL)

P5B

ATP13A4 ?

Specific language impairment (SLI),
autism spectrum disorders (ASD)
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CHAPTER 2: QUATERNARY STRUCTURE OF A C-TERMINALLY
TRUNCATED, PROTEOLYTICALLY ACTIVE FORM OF DJ-1

2.1 Introduction
DJ-1 belongs to the DJ-1/ThiJ/PfpI superfamily of proteins, members of which
often have chaperone and/or protease activity. Shared features of proteins in this
superfamily include a conserved cysteine residue in a “nucleophile elbow” strandloop-helix motif [106], a catalytic triad (cysteine, histidine and glutamate/aspartic
acid) in some (but not all) members, and the ability to form oligomers [106]. The
oligomeric state of these proteins varies widely ranging from dimers to trimers
and hexamers [106]. Data from gel filtration, sedimentation, and x-ray
crystallographic analysis indicate that purified recombinant DJ-1 exists primarily
as a homodimer [184, 185]. The monomeric subunit of DJ-1 is highly
homologous to the Pyrococcus horikoshii 1704 gene product (PH1704), a
bacterial cysteine protease which forms hexamers. DJ-1 has an additional α helix
(helix 8) at the C-terminus compared to PH1704. A recent study has shown that
a truncated form of DJ-1 (15 amino acids cleaved at the C terminus, resulting in
the removal of helix 8 has much greater protease activity compared to full-length
DJ-1 [46]. This C-terminally truncated form of DJ-1 (DJ-1Δ15) was found to
accumulate in dopaminergic cells exposed to oxidative stress, leading Chen et al.
to conclude that full-length WT DJ-1 is in fact a zymogen that becomes activated
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via a redox-sensitive mechanism [46]. Importantly, however, it is not known
whether DJ-1Δ15 has the ability to form a hexamer, or whether such a hexameric
structure is responsible for the observed protease activity.
We hypothesized that human DJ-1Δ15 adopts a hexameric structure similar to
that of PH1704. To address this hypothesis, we analyzed the quaternary
structure

of

DJ-1Δ15

using

PyMOL,

Western

blotting,

analytical

ultracentrifugation (AUC) and native PAGE gel electrophoresis. Our results
suggest that DJ-1Δ15 can form an oligomeric species that is larger than a
homodimer (potentially a hexamer), whereas full-length DJ-1 does not form a
hexamer because helix 8 prevents a conformational change that is required for
hexamer assembly.

2.2 Materials and Methods
2.2.1 Materials
The bicinchoninic acid (BCA) protein assay kit was obtained from Pierce
Biotechnology (Rockford, IL). The ECF substrate was purchased from GE
Healthcare (Piscataway, NJ). Coomassie brilliant blue R250 and SDS were
obtained from Amresco (Solon, OH). Trizma base, 2-Mercapto ethanol,
ammonium persulfate (APS) and glycine were purchased from Sigma-Aldrich (St.
Louis, MO). Isopropyl-β-D-thiogalactopyranoside (IPTG) and ampicillin were
purchased from Gold Biotechnology (St. Louis, MO).
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2.2.2 Antibodies
The following antibodies were used in these studies: mouse anti human DJ-1
(3E8) (Enzo Life Sciences, Farmingdale, NY. Clone), secondary anti mouse IgG
conjugated with alkaline phosphatase (Promega, Madison, WI, USA).
2.2.3 Preparation of the WT DJ-1 and DJ-1Δ15 constructs
A cDNA encoding wild-type (WT) DJ-1 was amplified by PCR and subcloned as
a BamHI – Xho I fragment into the vector pGEX-6P-1, yielding the construct,
pGEX-6P-1 GST DJ-1, which encodes an N-terminal GSH S-transferase (GST)
fusion with DJ-1 (GST DJ-1), by Dr. John Hulleman, a former graduate student in
the Rochet lab. A cDNA encoding DJ-1Δ15 was generated via PCR using a
reverse primer that included a stop codon after codon 174 and subcloned as a
BamHI – Xho I fragment into pGEX-6P-1, yielding the construct, pGEX-6P-1 GST
DJ-1Δ15. To develop a system for generating DJ-1Δ15 without the GST tag,
cDNA encoding DJ-1Δ15 was

amplified by PCR using the reverse primer

referred to above and subcloned as an Xba I – Hind III fragment into the vector
pT7-7, yielding the construct pT7-7 DJ-1Δ15. The sequence of the aSynencoding insert in each construct was verified using an Applied Biosystems (ABI
3700) DNA sequencer (Purdue University).
2.2.4 Purification of recombinant human WT DJ-1 and DJ-1Δ15
constructs
Cells of the BL21 (DE3) strain of Escherichia coli were transformed with DJ-1
expression constructs by electroporation. To prepare GST-WT DJ-1 and GSTDJ-1Δ15, the cells were grown to an OD600 of 0.4 - 0.6 in LB plus ampicillin (100
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μg/mL) at 37 °C, and IPTG was added to a final concentration of 1 mM. The cells
were grown under inducing conditions for 18 h at 18°C, harvested by
centrifugation, and resuspended in buffer A (25 mM KPi, pH 7.0, 200 mM KCl, 15
mM 2-mercaptoethanol (2-ME)). The cells were lysed by the addition of lysozyme
(1 mg/mL), incubated on ice for 30 min, and run through a French 86 pressure
cell (p.s.i. > 1000) (Thermo Electron Corporation, Waltham, MA). After
centrifugation (20,000 g, 20 min), the supernatant was applied to a GSTPrep FF
column (GE Healthcare). GST DJ-1 was eluted in 250 mM Tris HCl, pH 8.0, 500
mM NaCl, and 0.3% [w/v] reduced GSH. Fractions most highly enriched with
GST DJ-1 were identified by measuring the OD280 and pooled. The pooled
fractions were dialyzed against buffer A plus 2-ME (0.25 mM) to remove excess
GSH. The overall protein concentration was determined with a BCA protein
assay, and the fusion protein was cleaved with PreScission™ Protease
(GEHealthcare, 16 h, 4°C, 1 unit protease:133 μg DJ-1). Untagged DJ-1 was
separated from free GST and residual protease (which contains an uncleavable
GST tag) by elution from a GSTPrep FF column equilibrated with buffer A.
Fractions most highly enriched with DJ-1 were identified by sodium dodecyl
sulfate polyacrylamide gel electrophoresis (SDS PAGE) with Coomassie blue (R250) staining and pooled. The purity of the final protein sample was estimated to
be approximately 95% by Coomassie Blue staining.
To prepare pT7-7-WT DJ-1and pT7-7-DJ-1Δ15, the cells were grown to an
OD600 of 0.6 - 0.8 in LB plus ampicillin (100 μg/mL) at 37 °C, and expression of
the DJ-1 gene was induced by adding isopropyl-β-D-thiogalactopyranoside
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(IPTG, 1 mM). The cells were grown under inducing conditions for 4 h at 37 °C,
harvested

by

centrifugation,

resuspended

in

buffer

B

(50

mM

tris(hydroxymethyl)aminomethane (Tris) HCl, pH 7.4, 100 mM NaCl, 5 mM 2ME),
and lysed with a French pressure cell (p.s.i. > 1000) (Thermo Electron
Corporation, Waltham, MA). After centrifugation, DJ-1 was partially purified from
the supernatant by successive ammonium sulfate precipitations (70% saturation
followed by 90% saturation). The pellet from the second ammonium sulfate
precipitation was resuspended in buffer B, and the protein solution was applied to
a diethylaminoethyl (DEAE) Sepharose (GE Healthcare, Piscataway, NJ) anion
exchange column equilibrated with buffer B. Fractions in the flow-through
containing DJ-1 were identified by SDS PAGE with Coomassie Blue staining.
All purified DJ-1 samples were supplemented with glycerol (5%, [v/v]) and 2ME
(2 mM), and aliquots (1-2 mg/ml) were flash-frozen and stored at -80 °C. DJ-1
proteins were subsequently prepared for analysis by thawing followed by buffer
exchange or dialysis (there was no additional freezing or storage of the protein at
4 °C unless otherwise specified). The concentration of dialyzed DJ-1 samples
was estimated using the BCA assay.
2.2.5 PDB Files used for PyMOL analysis
PyMOL analyses were carried out using the following Protein Data Bank (PDB)
files: 1P5F, human WT DJ-1 [106]; 1G2I, PH1704 [112].
2.2.6 Analytical ultracentrifugation
DJ-1Δ15 (purified from E. coli BL21 DE3 expressing the pGEX-6P-1 construct or
the pT7-7 construct) was dialyzed in 50 mM Tris-Cl, 150 mM NaCl, pH 7.4 for 16
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h at 4 ºC. DJ-1Δ15 purified from E. coli expressing the pGEX-6P-1 construct
interacts with E.coli ATPase subunits to form a high molecular weight complex
(see Chapter 3). To remove this complex (and thus enable us to focus solely on
DJ-1Δ15 self-assembly), the protein was centrifuged at 100,000xg for 2 h at 4 ºC.
The supernatant was recovered and the protein concentration was estimated
using the BCA Protein Assay kit. The protein solution was then analyzed by
analytical ultracentrifugation (AUC) at the

Purdue Biophysical Analysis

Laboratory (BAL). DJ-1Δ15 purified from E. coli expressing the pT7-7 construct
was dialyzed as above and analyzed via AUC without the sedimentation step
described above. AUC was carried out at 50,000 rpm on a Beckman-Coulter
ultracentrifuge, XLI (Beckman-Coulter, CA). Sedimentation was monitored with
both Rayleigh Interference and absorbance optics. Protein (concentration, 0.5-2
mg/mL) was characterized at 20ºC for 12 h in 50 mM Tris-HCl, pH 7.5, 150 mM
NaCl and 1 mM 2ME.

Sedimentation coefficients and apparent molecular

weights, c(s), were determined using SEDFIT v. 12.43 [186, 187].
2.2.7 Size-exclusion chromatography with multi-angle light
scattering (SEC-MALS)
SEC-MALS analysis of DJ-1Δ15 was carried out at the BAL. DJ-1Δ15 was
dialyzed in 2 L of 50 mM Tris-HCl, pH 7.5, 150 mM NaCl and 1 mM 2ME (same
buffer as AUC above). A solution of the protein (1-4 mg/mL) at 0.5 mL/min was
applied onto a Superdex-200 column 10/300 GL (GE Healthcare) connected to
an ultra violet (UV) absorbance detector, a refractive index refractometer, and a
light scattering (LS) detector. Absolute molecular weights of species eluted from
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the column were determined using Wyatt’s Astra software, and the relative
amount of each species was assessed from the areas under the chromatogram
peaks
2.2.8 SDS-PAGE and native PAGE
DJ-1Δ15 (purified from E. coli BL21 DE3 expressing the pGEX-6P-1 construct or
the pT7-7 construct) was dialyzed in 50 mM Tris, 50 mM NaCl, pH 7.5 for 16 h at
4 ºC. The protein concentration was estimated using the BCA Protein Assay kit,
and equal amounts of protein (3 μg) were analyzed via electrophoresis on an 8%
(w/v) native polyacrylamide gel (no SDS or reducing reagent in either the sample
buffer or the running buffer, and the samples were not boiled). Alternatively, the
protein samples were analyzed via electrophoresis on a 12% (w/v) SDS PAGE
gel. The non-denaturing gel was run at 4 ºC at 80-100V for 2-3 h, whereas the
SDS PAGE gel was run at 22 ºC at 80-115V for 1.5 h. The gels were stained
using Coomassie Brilliant Blue dye for 20 min at 22 ºC and de-stained using a
solution of methanol, acetic acid and water (3:1:6), (v/v). Gel images were
obtained and analyzed using a Typhoon imaging system (GE Health Sciences,
Piscataway, NJ, USA).
2.2.9 Western blotting
DJ-1 samples were assayed for protein concentration using the BCA Protein
Assay Kit, and equal amounts of protein were separated via SDS–PAGE on a 4–
20% (w/v) polyacrylamide gel. The proteins were transferred to a 0.2 μm
polyvinylidene fluoride (PVDF) membrane, which was then probed with a primary
antibody specific for DJ-1 (1: 4000). The membrane was treated with a
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secondary anti-mouse alkaline phosphatase-conjugated antibody (1: 6000).
Chemifluorescence images were obtained and analyzed using a Typhoon
imaging system (GE Health Sciences, Piscataway, NJ, USA).

2.3 Results
2.3.1 Full-length DJ-1 cannot form a hexamer due to steric
hindrance involving helix 8.
Helix 8 of full-length DJ-1 is missing on PH1704, a bacterial cysteine protease
that is highly homologous to DJ-1 and has been shown to form a hexamer (Fig
2.1). We hypothesized that the absence of a C-terminal helix on PH1704 as
opposed to the presence of helix 8 on full-length DJ-1 could account for why
PH1704 forms a hexamer whereas DJ-1 forms a homodimer. To address this
hypothesis, we overlaid models of the three-dimensional (3D) structures of fulllength DJ-1 and PH1704 ‘half hexamers’ using PyMOL. Analysis of the overlaid
structures revealed that full-length DJ-1 is unable to form a PH1704-type
hexamer because of steric conflicts involving helix 8 (Fig. 2.2A).
2.3.2 The results of a PyMOL analysis suggest that DJ-1Δ15 can
adopt a hexameric structure.
The monomeric subunit of DJ-1Δ15 is highly homologous to the Pyrococcus
horikoshii 1704 gene product (PH1704) [112]. Because DJ-1Δ15 lacks helix 8
(Fig. 2.2B), similar to PH1704 which exists as a hexamer, we hypothesized that
DJ-1Δ15 can adopt a hexameric structure. To address this hypothesis, a model
of the 3D structure of full-length DJ-1 was loaded into PyMOL, and the 15 C-
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terminal amino acid residues were deleted to generate a model of the DJ-1Δ15
3D structure. Analysis of the model revealed that DJ-1Δ15 could form a closed
hexamer (Fig 2.3). Formation of this closed hexamer was made possible by (i)
the truncation of helix 8, and (ii) a 90° rotation between two DJ-1Δ15 subunits at
the interface that is homologous to the subunit interface of the full-length DJ-1
homodimer. The interfaces of the unrotated and rotated subunits of members of
the DJ-1/ThiJ/PfpI superfamily have been referred to as patch 1 and patch 1’,
respectively [113]. In the absence of the subunit rotation, DJ-1Δ15 dimers
retained the patch 1 configuration and could only assemble to form an open
hexamer (Fig 2.4).
Further analysis of the closed DJ-1-Δ15 hexamer revealed that C106 and H126
on one subunit were positioned at distances of 9.5 Å and 5.5 Å (respectively)
from a glutamateresidue at position 84 of an adjacent subunit (E84’) (Fig 2.5A).
This positioning of C106, H126, and E84’ implied that the three residues could
potentially form a catalytic triad, similar to that of PH1704 in which residues C100
and H101 are positioned at distances of 7.3 Å and 2.6 Å (respectively) from E74’
(of an adjacent subunit (Fig. 2.5B). The two subunits carrying these residues
interact at a new interface, referred to as patch 2 [113].
2.3.3. Recombinant DJ-1Δ15, but not full-length WT DJ-1, forms
high molecular weight species that are larger than a homodimer
(SDS-PAGE/Western blot analysis).
Based on our PyMOL results (see above), we hypothesized that DJ-1Δ15 could
form high molecular weight species that are larger than a homodimer, in contrast
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to DJ-1. To address this hypothesis, full-length DJ-1 and DJ-1Δ15 were analyzed
by (i) SDS PAGE (denaturing and reducing) followed by Western blot analysis
using an antibody that recognizes both DJ-1Δ15 and full-length DJ-1; and (ii)
native PAGE (non-denaturing and non-reducing) with Coomassie blue staining.
As predicted, purified DJ-1Δ15 had a lower molecular weight compared to fulllength DJ-1 due to the truncation of the 15 amino acids from the C terminus
region (Fig 2.6). A Western blot showed the presence of high MW species in the
DJ-1Δ15 sample (Fig 2.7). In contrast, the results of native PAGE analysis
showed no significant high-order oligomer signal (corresponding to an oligomer
with an apparent molecular weight greater than that of dimeric DJ-1) in lanes
loaded with two different purified DJ-1 del15 samples (Fig. 2.8). Thus, the
Western blot results suggest that DJ-1Δ15 forms higher molecular weight
species, consistent with the results of our PyMOL analysis (see above), but the
native PAGE data suggest that oligomeric DJ-1Δ15 is a minor species and/or is
unstable under non-denaturing electrophoresis conditions.
2.3.4 Recombinant DJ-1Δ15 forms high molecular weight species
that are larger than a homodimer (analytical ultracentrifugation).
The next experiments were designed to investigate whether DJ-1Δ15 consists of
an equilibrium population of monomers, dimers, and hexamers (and potentially
also trimers). We hypothesized that DJ-1Δ15 forms distinct species with different
molecular weights. To address this hypothesis, DJ-1Δ15 was analyzed via AUC.
Sedimentation-velocity analysis of a sample of DJ-1Δ15 purified from E. coli as
an untagged protein (following expression of the pT7-7 construct) revealed the
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presence of three species with strikingly different sedimentation speeds,
corresponding to the DJ-1Δ15 monomer (1.8S), dimer (3.0S) and a high
molecular weight species (5.2 - 5.7S) (Fig 2.9). Similar results were obtained
upon sedimentation-velocity analysis of a sample of DJ-1Δ15 that was purified
from E. coli as a GST-tagged protein (following expression of the pGEX-6P-1
construct) and subsequently cleaved to remove the GST tag (Fig. 2.10). The
smaller peak (1.1S) detected in the DJ-1Δ15 preparation E. coli expressing the
pGEX-6P-1 construct might be a DJ-1Δ15 truncated species. The results further
showed that the distribution of DJ-1Δ15 among the different species varied with
protein concentration
In additional studies, a DJ-1Δ15 (untagged) sample was analyzed via SEC
MALS, a method that involves (i) the chromatographic fractionation of protein
species according to molecular weight, and (ii) monitoring protein elution by
measuring light scattering signals that increase with increasing molecular weight
of the eluted species. The results showed the presence of peaks eluting earlier
than the dimeric peak suggesting that DJ-1Δ15 formed species that were larger
than a homodimer (data not shown). In summary, these data further support our
conclusion from molecular modelling (PyMOL) studies that DJ-1Δ15 can form
high molecular weight species.

2.4 Discussion
In this chapter, we investigated whether DJ-1Δ15 can form oligomers that are
larger than a homodimer, both computationally and biochemically in a cell-free
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system. Our results suggest that DJ-1Δ15 has the ability to form high MW
oligomers, including potentially a hexamer. In addition, the results of PyMOL
analysis suggest that formation of DJ-1Δ15 hexamer may allow for the formation
of a catalytic triad by bringing E84 from one subunit in proximity to C106 and
H126 from another. Whether residue E84 is critical for DJ-1Δ15 to function as a
protease remains to be elucidated.
2.4.1 Full-length WT DJ-1 does not form a hexamer due to the
presence of helix 8 at the C-terminus.
DJ-1 belongs to a superfamily of proteins with the ability to form functional
oligomers (chaperones and/or proteases.

Purified recombinant DJ-1 exists

primarily as a homodimer [184, 185]. The monomeric subunit of DJ-1 is highly
homologous to the Pyrococcus horikoshii 1704 gene product (PH1704), a
bacterial cysteine protease which forms a hexamer. DJ-1 has an additional α
helix (helix 8) at the C-terminus compared to PH1704. The results of our PyMOL
analysis clearly showed that full-length DJ-1 cannot form a hexamer due to steric
hindrance involving this additional α helix.
Full-length DJ-1 has been reported to exist as a zymogen that becomes activated
as a result of the cleavage of the C-terminal helix via a redox-sensitive
mechanism [46]. The results of computational and biochemical analyses
suggested that DJ-1Δ15 has the ability to form oligomers that are larger than the
homodimer, including a hexamer (discussed in greater detail below). Chen at al
further predicted that the DJ-1Δ15 variant has an ‘unmasked’ active site involved
in proteolytic function [46]. Our results suggest that the truncation may convert
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the full-length zymogen into the proteolytically active form by enabling
conformational changes required for hexamer formation, which may in turn be
necessary for the assembly of a catalytic triad encompassing residues from
multiple subunits. The presence of helix 8 suggests that there is a selective
advantage to having DJ-1 only exist as an active protease under specific
conditions (e.g. high oxidative stress), whereas the zymogen design does not
appear to confer a selective advantage on PH1704.
2.4.2 Removal of 15 C-terminal amino acid residues facilitates
formation of a hexamer.
Our computational analysis via PyMOL showed that DJ-1Δ15 can readily form a
hexamer as a result of the removal of the 15 C-terminal amino acid residues.
This truncation allows for a 90° rotation between two subunits, resulting in the
conversion of the patch 1 interface to the patch 1’ interface. In turn, only DJ-1Δ15
dimers with a patch 1’ interface can undergo self-assembly to form a closed
hexamer (or trimer of dimers). In contrast, only an open hexamer could form
upon the self-assembly of dimers that have not undergone a 90° rotation to
generate the patch 1’ interface. An open hexamer would be predicted to have a
relatively low thermodynamic stability because (i) it lacks inter-subunit
interactions involved in forming a closed structure, and (ii) it may expose greater
hydrophobic surface area (i.e. at the unclosed ends of the open hexameric
structure) compared to a closed hexamer.
Taken together, these data suggest that the formation of a DJ-1Δ15 closed
hexamer (if it occurred in solution) would be made possible because of the
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absence of helix 8 and would involve a 90°rotation between two DJ-1 subunits,
converting patch 1 to patch 1’ in each of the three pairs of subunits constituting
the hexamer. Moreover, the formation of a DJ-1Δ15 hexamer would potentially
allow for the formation of a catalytic triad consisting of Cys 106 and His 126 from
one subunit and E84’ from an adjacent subunit at the patch 2 interface.
2.4.3 Hexamer formation by DJ-1Δ15 may be necessary for the
assembly of a catalytic triad involved in proteolysis.
The results of our PyMOL analysis also imply that hexamer formation by DJ1Δ15 may be necessary for the protease activity of this variant because a new
interface (referred to as patch 2) formed upon the assembly of a trimer of dimers
may lead to the formation of a catalytic triad, in contrast to the catalytic diad
proposed by Chen et al. [46]. Our results showed that closed hexamer formation
by DJ-1-Δ15 brings residue E84’ from one subunit in proximity to the other
residues of the potential catalytic triad, Cys106 and His 126 from another
subunit. Similarly, the relative positions of the three residues were the same in
patch 2 of the hexamer formed from unrotated DJ-1 del15 dimers (with a patch 1
interface rather than a patch 1' interface (data not shown). Future mutagenesis
studies will be aimed at determining whether the assembly of such a catalytic
triad is responsible for the observed protease activity of DJ-1-Δ15. Previous
studies indicated that the distance between the glutamate and cysteine in a
catalytic triad is ~2.6 Å and between glutamate and histidine is ~7 Å [188, 189].
Therefore the distances from E84’-C106 (9.5 Å) is larger than typical distances in
a catalytic triad. However, the distances may fall into the typical range as a result
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of conformational changes associated with hexamer assembly, and these cannot
be detected by PyMOL. Future research will be focused on exploring such
conformational changes involved in hexamer assembly via molecular dynamics
simulations.
2.4.4 DJ-1Δ15 oligomers larger than a homodimer exist in solution.
AUC results of DJ-1Δ15 suggested that large oligomeric species exist in solution,
and the abundance of these species relative to the monomeric or dimeric protein
is concentration-dependent. These results suggest that DJ-1Δ15 high order
oligomers are in rapid equilibrium with the monomeric and dimeric forms.
Furthermore, the presence of bands corresponding to large oligomers on an SDS
PAGE gel (detected by Western blotting) suggests that these oligomeric species
may be stabilized by covalent linkages. Future studies will be aimed at (i)
characterizing the equilibrium distribution of large oligomeric forms of DJ-1Δ15 in
greater detail, and (ii) identifying key intersubunit interactions necessary for the
assembly of these oligomeric species. Because the levels of DJ-1Δ15 high
molecular weight oligomers relative to the monomer or homodimer appear low
compared to the predicted levels of PH1704 hexamer [112], we infer that the
intersubunit contacts at patch 2 of DJ-1Δ15 may not be as optimal for stabilizing
a hexameric structure compared to those of the bacterial enzyme. Future
research will be aimed at addressing this hypothesis with a combination of
computational and mutagenesis studies. If the hypothesis is true, then this would
suggest that residues that could be involved in patch 2 interactions of DJ-1Δ15
may not have been subjected to selective pressure, perhaps because the
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formation of a hexamer is less important to the function of DJ-1 (or DJ-1Δ15)
compared to that of PH1704.

2.5 Conclusion
In summary, our data suggest that DJ-1Δ15 can potentially form high order
oligomeric species. Specifically, we showed via computational analysis that DJ1Δ15 potentially forms a closed hexamer by forming a new interface (patch 1’). In
contrast, full-length DJ-1 cannot adopt a hexameric structure due to steric
conflicts involving helix 8. Formation of the DJ-1Δ15 hexamer may be necessary
for the protease activity of this variant because the new interfaces formed upon
assembly of a trimer of dimers may lead to the formation of a catalytic triad.
Studies of DJ-1Δ15 in solution showed that DJ-1Δ15 forms oligomeric species
larger than a homodimer in a concentration-dependent manner. Further efforts
are underway to determine whether the formation of these high molecular weight
species is responsible for the observed protease activity of DJ-1Δ15.
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Figure 2.1 Structural model of the PH1704 hexamer.
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Figure 2.2 Overlaid structures of PH1704 half-hexamer (1G2I, green) and WT DJ-1
(1P5F, cyan) or DJ-1Δ15.
(A) WT DJ-1 does not form a hexamer because helix 8 causes steric hindrance at the patch 1’
interface. Helix 8, C106, H126, and E84’ of DJ-1 are shown. (B) DJ-1Δ15 overlays well with PH1704
due to the absence of helix 8.
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Figure 2.3 Structural model showing a closed hexamer that could be formed by DJ 1Δ15.
DJ-1Δ15 can form a closed hexamer as a result of removal of the 15 C-terminal residues and
a 90° rotation between two subunits, allowing for conversion of the patch 1 interface to the
patch 1’ interface. This conformational change is necessary for patch 2 interactions leading to
the assembly of a hexamer (trimer of dimers) with a closed structure. (Structural model
generated by Fletcher Jones).
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Figure 2.4 Structural model showing an open hexamer that could be formed by DJ1Δ15.
DJ-1Δ15 is expected to form an open hexamer upon self-assembly in the absence of a 90°rotation
between two subunits, so that the patch 1 interface is not converted to the patch 1’ interface. (Structural
model generated by Fletcher Jones).
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Figure 2.5 Potential DJ-1Δ15 catalytic triad.
(A) Formation of the DJ-1Δ15 hexamer brings a glutamate residue 84 (E84’) from one subunit to within 9.5 Å of
cysteine 106 (C106) and 5.5 Å of histidine (H126), and this positioning of the three residues may result in the
assembly of a catalytic triad. (B) PH1704 forms a catalytic triad with E74’ from one subunit placed within 7.3 Å of C100
and 2.6 Å of H101.
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Figure 2.6 SDS-PAGE gel showing that DJ-1Δ15 has a lower molecular weight compared to WT DJ-1.

The following proteins (3 μg) were analyzed: WT DJ-1 purified from E. coli expressing a pGEX-6p-1 construct;
DJ-1Δ15 purified from E. coli expressing a pGEX-6p-1 construct; and DJ-1Δ15 purified from E. coli
expressing a pT7-7 construct. The gel was stained with Coomassie Brilliant Blue R-250. N=2
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Figure 2.7 Western blot of SDS-PAGE gel showing evidence of DJ-1Δ15 oligomerization.
WT DJ-1 and DJ-1Δ15 were ultracentrifuged at 100,000 rpm (300,000 xg) at 4ºC for 30 min. The supernatant
(supern) was carefully removed and analyzed via Western blotting using a DJ-1 specific primary antibody (1:4000).
N=2
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Figure 2.8 Native PAGE gel showing that high order oligomer are only minor in two different preparation
of DJ-1Δ15. N=2
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Figure 2.9 Analysis of DJ-1Δ15 purified as an untagged protein via AUC.
(A) Sedimentation-velocity data showing total protein signal (interference fringes) versus radial distance in an
ultracentrifugation cell with DJ-1Δ15 at different sedimentation times. (B) Plot showing the distribution of species
with different sedimentation coefficients (S) at three different concentrations of protein (0.75 mg/ml, 0.38 mg/ml
and 0.19mg/ml). N=2
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Figure 2.10 AUC analysis of DJ-1Δ15 purified as a GST-tagged protein and subsequently cleaved for tag
removal).
(A) Sedimentation-velocity data showing total protein signal (interference fringes) versus radial distance in an
ultracentrifugation cell with DJ-1Δ15 at different sedimentation times. (B) Plot showing the distribution of species
with different sedimentation coefficients (S) at two different concentrations of protein (1.35 mg/ml and 0.65 mg/ml).
N=1

53

CHAPTER 3: DJ-1 INTERACTS WITH E.COLI F1 ATP SYNTHASE

3.1 Introduction
DJ-1 has been implicated in many cellular protective functions including a
peroxiredoxin function and the ability to act as molecular chaperone [108, 141,
142, 190], but the exact mechanism for its neuroprotective function is unknown.
Molecular chaperones are large a class of proteins that suppress protein
misfolding, aggregation and aid in refolding denatured proteins [191, 192].
Included in this large class of proteins are multiple heat shock proteins (Hsps)
[191, 192], many of which function in an ATP-dependent manner [191, 192].
Another class of proteins, peroxiredoxin (Prxs), functions as both molecular
chaperones and peroxidases [193]. A number of Prxs have been shown to form
high molecular weight structures, up to five dimers linked by hydrophobic
interactions [194]. The dual functions of Prxs are modulated by oxidative stress,
which can induce dramatic changes in quaternary structure [195].
DJ-1 has been described as an atypical Prx that scavenges hydrogen peroxide
(H2O2) via oxidation of Cys106 [190]. The reaction of cysteinyl thiolates with H2O2
yields multiple oxidation forms: sulfenic acid (–SOH), sulfinic acid (–SO2H),
sulfonic acid (–SO3H), and disulfide (–S-S–), including glutathione S-conjugate
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and disulfide S-oxides [196-199]. Hyperoxidation of Prxs to the sulfinic acid form
results in inactivation. In some cases this inactivation can be reversed by
sulfiredoxin, a protein that provides an ATP molecule which is a target for
nucleophilic attack by the cysteine sulfinic acid, resulting in the formation of
sulfinic acid phosphoryl ester intermediate. In turn, reaction of this intermediate
with a sulfiredoxin cysteine residue (or a small-molecule reductant) releases a
phosphate and results in the formation of a thiosulfinate intermediate, which can
be reduced to regenerate the sulfenic acid form of the Prx [200] .
Analysis of the DJ-1 crystal structure revealed a previously undescribed potential
ATP binding site that included two arginine residues, Arg 28 and Arg 48, near the
oxidizable Cys106 residue. These residues could potentially serve as binding
sites for the beta and gamma phosphates of ATP. A former graduate student in
the lab, Kristen Lesniak, showed that a nonhydrolyzable analog of ATP (ATPγS)
stabilized DJ-1 in a pulse-proteolysis assay (unpublished data). In addition, a
preparation of recombinant human wild-type DJ-1 purified from E. coli was found
to bind and hydrolyze ATP and GTP, but not CTP, TTP, or ADP.
In this study we carried out a series of biochemical experiments to determine the
source of the ATPase activity in our DJ-1 preparations. Our results show that DJ1 interacts with E.coli F1 ATP synthase and this interaction may be relevant to
DJ-1 chaperone activity. Our data also suggest that the reduced form of DJ-1
preferentially interacts with F1 ATPase. These findings provide new insights into
the biochemical mechanism by which DJ-1 preserves mitochondrial function in
neurons exposed to PD-related insults – namely, by interacting with F1 ATPase,
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a protein complex that is structurally and functionally well conserved between E.
coli and eukaryotic mitochondria.

3.2 Materials and Methods
3.2.1 Materials
The bicinchoninic acid (BCA) protein assay kit was obtained from Pierce
Biotechnology (Rockford, IL). The ECF substrate was purchased from GE
Healthcare (Piscataway, NJ).

Coomassie Brilliant Blue R250 and SDS were

obtained from Amresco (Solon, OH). All other chemicals were purchased from
Sigma-Aldrich (St. Louis, MO).
3.2.2 Antibodies
The following antibodies were used in these studies: mouse anti human DJ-1
(3E8) (Enzo Life Sciences, Farmingdale, NY), secondary anti mouse IgG
conjugated with alkaline phosphatase (Promega, Madison, WI, USA, Cat. #
S3721), secondary anti rabbit IgG conjugated with alkaline phosphatase
(Promega, Madison, WI, USA, Cat # S3731). Anti ATP beta subunit (ATPB)
(7E3F2) (Abcam, Cambridge, MA, USA).
3.2.3 DJ-1 protein purification
DJ-1 was purified as explained earlier in Chapter 2.
3.2.4 A continuous fluorimetric assay to measure ATPase activity
ATPase activity was monitored via a continuous fluorimetric assay. In the
presence of phosphate, nucleoside phosphorylase (PNP) will convert 7-methylguanosine (M7Guo), a fluorescent substrate, to 7-methyl-guanine (M7Gua), a
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non-fluorescent molecule, thus decreasing the fluorescence [201]. WT DJ-1 was
dialyzed against 2 L of 50 mM Tris-HCl, pH 7.5, 50 mM NaCl, and 1 mM MgCl2.
Protein concentration was determined using the BCA assay, and 15 μg of DJ-1
was mixed with 7-methyl-guanosine (M7Guo) (4 mM), 0.1 units of PNP, 1 mM
MgCl2, and 1 mM ATP in a 1 mL quartz spectrometer cuvette (Sigma Aldrich, St.
Louis MO). The decrease in fluorescence was observed at 410 nm (the excitation
wavelength was 300 nm) using a FluoroMax 3 fluorescence spectrophotometer
(HORIBA Jobin Yvon, Edison, NJ).
3.2.5 Filtration of DJ-1 samples
WT DJ-1 was dialyzed against 2 L of 50 mM Tris-HCl, pH 7.5, 50 mM NaCl, and
1 mM MgCl2. The protein was later applied to a 100 kDa spin filter (Millipore
Billerica, MA). The filter was spun at 2,000 xg for 4 min at 4 ºC. The filtrate was
recovered, and protein concentration was determined using the BCA kit before
analysis of ATPase activity.
3.2.6 Size Exclusion Chromatography (SEC)
WT DJ-1 (~1 mg/mL final concentration) was dialyzed against 50 mM Tris-HCl,
pH 7.5, 50 mM NaCl, and 1 mM MgCl2, and an aliquot (200 μg) was applied to a
Superdex 200 10/30 size exclusion chromatography (SEC) column (GE
Healthcare). The protein was eluted with the same buffer used for dialysis at a
flow rate of 0.5 mL/min, monitoring absorbance at 280 nm. Apparent molecular
weights of eluted proteins were determined using a calibration curve established
with the following standards: blue dextran (>600 kDa), bovine serum albumin
(BSA, 66.2 kDa), ovalbumin (43 kDa), and lysozyme (14.3 kDa).
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3.2.7 Ultracentrifugation
WT DJ-1 was dialyzed in 2 L of a buffer consisting of 50 mM Tris-HCl, pH 7.5, 50
mM NaCl, and 1 mM MgCl2 for 16 h at 4ºC. The protein was then ultracentrifuged
at 47,000 rpm (100,000 xg) at 4ºC for 2 h using a Beckman ultracentrifuge (Dr.
Chris Hrycyna, Purdue University, Chemistry). The supernatant was removed,
and the pellet was resuspended in dialysis buffer.
3.2.8 Sucrose gradient centrifugation
A series of sucrose solutions (5%-50%, w/v) was prepared in 50 mM Tris-HCl,
pH 7.5, 50 mM NaCl, 1 mM MgCl2. An aliquot of each solution (2 mL) was
carefully layered into an ultracentrifuge tube (16x89mm, Beckman), starting with
the 50% solution at the bottom. To separate high-MW species in the DJ-1
preparation from the predominant homodimer, the protein sample was loaded on
the 5% sucrose solution (top-most layer of the gradient), and ultracentrifugation
was carried out at 40,000 rpm (274,000 xg) for 18 h at 4 ºC. Fractions of about
500 μL were collected from the bottom of the tube by puncturing the tube bottom.
The samples were analyzed via Western blotting using antibodies specific for DJ1 and ATPB.
3.2.9 Western blotting
After measuring the concentration of protein solutions using the BCA Protein
Assay Kit (Pierce Biotechnology, Rockford, IL, USA), equal amounts of protein
were separated via SDS–PAGE on a 4-20% or 12% (w/v) polyacrylamide gels.
Due to the low amount of protein in the sucrose gradient fractions, the protein
concentration of these fractions was not determined; instead, an equal volume
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(12 μL) of each fraction was loaded on the gel. The proteins were transferred to a
0.2 μm polyvinylidene fluoride (PVDF) membrane, which was then probed with a
primary antibody specific for DJ-1 (1:4000), oxidized DJ-1 (1:5000), GST
(1:5000), or ATPB (1:5000). The membrane was treated with a secondary antimouse or anti-rabbit alkaline phosphatase-conjugated antibody (1:6000) or using
a secondary fluorescence goat anti-rabbit/Alexa Fluor 488 (Life technologies,
Carlsbad CA) and goat anti-mouse Alexa Fluor 594 (Life technologies, Carlsbad
CA). Images were obtained and analyzed using a Typhoon imaging system (GE
Health Sciences, Piscataway, NJ, USA).
3.2.10 Transmission Electron Microscopy (TEM)
Gradient fractions (10 μL) were deposited on glow–discharged carbon-coated
copper grids (FCF400-Cu), and the grids were rinsed with three drops of 50 mM
Tris-HCl, pH 7.5, 50 mM NaCl, and 1 mM MgCl2. The grids were then negatively
stained with 1% (w/v) uranyl-acetate. Images were generated using an electron
microscope

(CM200

transmission

electron

microscope

(TEM),

(Phillips,

Amsterdam, Netherlands) operated at 200 kV, in collaboration with Dr. Lia
Stanciu (Department of Materials Engineering, Purdue University).
3.2.11 Mass Spectrometry
Samples obtained from the 50% sucrose gradient fraction were first denatured in
a buffer consisting of 8 M urea, 50 mM Tris-HCl, pH 7.5, 50 mM NaCl, and 1 mM
MgCl2. To reduce disulfide bonds, DTT was added to a final concentration of 10
mM, and the samples were incubated at 37 ºC for 1 h. Iodoacetamide was added
to a final concentration of 20 mM, and the samples were incubated at 22 ºC for 1
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h to alkylate the reduced cysteine residues. After dilution with a five-fold excess
of buffer, the samples were incubated with trypsin (10 μg per mg of protein) for
12-16 h at 37 ºC. The samples were then desalted using a C-18 capillary column
packed with 5 μm C18 Magic bead resin (Michrom; 75 μm i.d. and 12 cm of bed
length) and analyzed via mass spectrometry (UPLC: EASY-nLC 1000 Liquid
Chromatograph (Thermo Scientific). Mass Spec: Thermo Fisher LTQ-Orbitrap
Velos) in collaboration with Lingfei Zeng and Dr. Andy Tao (Department of
Biochemistry, Purdue University).
3.2.12 Database search
The LTQ-Orbitrap raw files were searched directly against the human, E. coli or
S. japonicum database using SEQUEST on Proteome Discoverer (Version 1.4,
Thermo Fisher). Proteome Discoverer created DTA files from raw data files with
minimum ion threshold 15 and absolute intensity threshold 50. Peptide precursor
mass tolerance was set to 10 ppm, and MS/MS tolerance was set to 0.6 Da.
Search criteria included a static modification of cysteine residues of +57.0214 Da
and a variable modification of +15.9949 Da to include potential oxidation of
methionine. Searches were performed with full tryptic digestion and allowed a
maximum of two missed cleavages on the peptides analyzed from the sequence
database. False discovery rates (FDR) were set to 1% for each analysis. Two
peptides with high confidence were considered as solid evidence of the protein
ID.
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3.3 Results
3.3.1 A preparation of recombinant WT DJ-1 loses ATPase activity
upon filtration.
To preserve our DJ-1 preparation, we filtered the protein through a filter with a
molecular weight cutoff of 100 kDa to remove any microbial contaminants. We
tested the ATPase activity of our DJ-1 preparation before and after filtration using
a continuous fluorescence assay (PNP). Surprisingly, our results showed that the
ATPase activity of the DJ-1 preparation was absent in the filtrate (Fig 3.1). These
data suggested that the ATPase activity was associated with either a high
molecular weight form of DJ-1 or another high molecular weight protein in the DJ1 preparation.
To further confirm the filtration results, we used a size exclusion chromatography
(SEC) approach. The homodimer purified using a superdex-200 column was
analyzed for ATPase activity using the PNP assay with or without ATP. The
results showed that homodimer ATPase activity, and doubling the amount of the
DJ-1 homodimer used in the assay did not change the results (Fig 3.2).
Taken together, these results suggest that (i) the ATPase activity was associated
with either a high molecular weight form of DJ-1 or another high molecular weight
protein in the DJ-1 preparation, and (ii) DJ-1 homodimer, isolated via SEC did not
show ATPase activity.
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3.3.2 A preparation of recombinant WT DJ-1 contains DJ-1immunoreactive high molecular weight (high-MW) species.
Our next goal was to determine the molecular basis for the ATPase activity in our
DJ-1 preparations. We hypothesized that DJ-1 forms a high molecular weight
complex under oxidizing conditions, similar to Prx [195]. In addition, we
hypothesized that the high MW form of DJ-1 has ATPase activity, based on our
observation that the ATPase activity in our DJ-1 preparations could be removed
by filtration. To address this hypothesis, we first examined whether a portion of
the DJ-1 in our recombinant protein preparations existed as a high-MW complex.
We separated high-MW species using two well-established separation methods,
ultracentrifugation and sucrose gradient ultracentrifugation.
As an initial approach to separate WT DJ-1 high-MW species, the dialyzed
protein was ultra-centrifuged. The dimeric DJ-1 fraction (supernatant) was
removed by careful pipetting, while the high-MW species fraction (pellet) at the
bottom of the tube was resuspended in buffer. The supernatant and pellet
fractions and an aliquot of WT DJ-1 with mixed species (not ultracentrifuged
‘uncentr’) were fractionated on an SDS PAGE gel and analyzed via Western
blotting with an antibody specific for DJ-1. Our results showed evidence of higher
amounts of DJ-1-positive high molecular weight bands in the pellet fraction
compared to the supernatant (S/N) fraction. In addition, there was a decreased
intensity of monomeric DJ-1 in the pellet fraction (Fig 3.3).
As an alternative method, we analyzed our DJ-1 samples via sucrose gradient
centrifugation. Dialyzed WT DJ-1 was overlaid on the top-most sucrose fraction

62
(5%). After centrifugation, three fractions from each of several zones of the
gradient (corresponding to sucrose percentages of 20%, 30%, and 50%, v/v)
were collected, and an aliquot of each fraction (500 μL) was analyzed via
Western blotting. Our results showed higher levels of high-MW species in the
50% sucrose fraction compared to the other fractions (Fig 3.4). Taken together,
our results suggest that our DJ-1 preparation contains DJ-1-immunoreactive
high-MW.
3.3.3 The high MW fraction from our WT DJ-1 preparation contains
ATPase activity.
Our next goal was to examine whether the ATPase activity observed in our
preparations of human WT DJ-1 was associated with the high-MW species
described in the previous section. Based on our earlier observation that DJ-1
samples lost the ability to hydrolyze ATP upon filtration, we hypothesized that the
ATPase activity would track with fractions enriched with high-MW species. To
address this hypothesis, high-MW species were separated using the two
ultracentrifugation methods described above.
The fractions obtained via ultracentrifugation (non-sucrose gradient) were
analyzed for the release of inorganic phosphate in the absence or presence of
ATP using a continuous fluorescence assay (PNP). The results showed that the
pellet fraction had a higher ATPase activity, whereas the S/N fraction showed no
ATPase activity (Fig 3.5).
Data from the sucrose gradient ultracentrifugation analysis revealed that fractions
at the bottom of the gradient (with ~40-45% sucrose) had a relatively high level of
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ATPase activity, whereas fractions with lower percentages of sucrose showed
markedly less ATPase activity (Fig 3.6).
Taken together, these results suggest that a high-MW, DJ-1-immunoreactive
species in our preparations of recombinant human WT DJ-1 purified from E.coli
has ATPase activity.
3.3.4 Sucrose fractions with ATPase activity contain ring-like
structures.
Previous studies have reported that DJ-1 acts a molecular chaperone [141, 142],
and a number of molecular chaperones have been shown to form high molecular
species [194]. The next set of experiments was designed to determine the
structural properties of high-MW weight protein species in sucrose fractions with
ATPase activity. As one possibility, we hypothesized that DJ-1 might undergo
self-assembly to form a high-MW chaperone, perhaps under oxidizing conditions
as described for various peroxiredoxins [195], and such a DJ-1 high-MW
chaperone might have ATPase activity. Alternatively, we considered the
possibility that DJ-1 might interact with another high MW protein with ATPase
activity. To address these hypotheses, we analyzed the fractions obtained by
sucrose gradient ultracentrifugation via electron microscopy (EM). Our results
showed that fractions with the highest percentage of sucrose (40-45%), which
also showed high ATPase activity (see above), consisted of ring-like structures
with a diameter of approximately 20-50 nm (Fig 3.7). In contrast, these structures
were absent from fractions with lower percentages of sucrose and negligible
ATPase activity. Similarly, we did not observe ring-like structures in the
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supernatant obtained via ultracentrifugation of a DJ-1 preparation in the absence
of sucrose (this supernatant fraction consisted mainly of DJ-1 homodimer and did
not show any ATPase activity). Moreover, a sample of purified GST lacked the
ring-like structures (data not shown).
From these findings, we infer that high-MW species present in fractions
with ATPase activity consist of ring-like structures, whereas these structures are
absent from fractions containing homodimeric DJ-1, which also lack ATPase
activity. Our data show that the ATPase activity present in the high-MW fraction
of our DJ-1 preparations tracks with ring-like structures observable by EM,
raising the possibility that the ATPase activity could be associated with these
structures.
3.3.5 Analysis of the high MW fraction of our DJ-1 preparation by
mass spectrometry revealed the presence of E. coli F1 ATP
synthase subunits.
As mentioned above, we considered two hypotheses to account for the presence
of DJ-1 protein and ATPase activity in a high MW fraction obtained from our DJ-1
preparation by sucrose gradient sedimentation: first, that DJ-1 might oligomerize
to form a high MW chaperone with ATPase activity; and second, that DJ-1 might
interact with another high-MW protein with ATPase activity. Two key findings led
us to favor the second hypothesis: (i) we were unable to generate a high-MW
form of DJ-1 with ATPase activity upon incubation under oxidizing or reducing
conditions; and (ii) a preparation of the C106A mutant of DJ-1 also had ATPase
activity, contrary to our prediction that the oxidation of this residue might play a
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role in the conversion of DJ-1 to a high-MW form by analogy with the selfassembly mechanism of redox-sensitive peroxiredoxins [195].
To determine the protein composition of the high-MW (high sucrose) fraction
from our DJ-1 preparation, a sample of the high MW fraction was subjected to
tryptic digestion and analyzed via mass spectrometry (MS) in collaboration with
Dr. Andy Tao (Purdue University). A sample of recombinant (purified) GST was
also analyzed via MS as a control. The peptide masses obtained from the MS
analysis were searched against three databases: human, E.coli and Schistosoma
japonicum (the species from which is derived the GST tag). The MS data
revealed the presence of DJ-1 in the human database search, with a score of
93.41. The E.coli database search revealed the presence of E. coli F1 ATP
synthase subunits: alpha α, beta β, delta ߜ, and gamma γ. Highest scores were
obtained for the β and α subunits (Table 3.1), which are known to assemble into
ring-like structures. Other E. coli proteins revealed by the MS analysis included
F0 subunit b, in addition to a number of other ATP-binding proteins (Table 3.1).
The Schistosoma japonicium database search revealed the presence of GST
with a score of 210.52. Since we did not observe any ATPase activity with GST
(Fig 3.8), we predicted that we would not detect ATPase subunits in the GST
mass spec data. This was confirmed. These results suggest that the proteins in
the high-MW fraction of our DJ-1 preparation include DJ-1, E.coli F0 and F1
ATPase subunits, other ATP-binding proteins, and GST. Therefore, we
concluded that (i) DJ-1 might be interacting with other E.coli proteins in our
recombinant protein preparation to form a complex that has ATPase activity and
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potentially exists as ring-like structures and (ii) purified GST protein lacked the
ATPase activity.
3.3.6 Analysis of the high MW fraction of our DJ-1 preparation by Western
blotting revealed the presence of the beta subunit of E. coli F1 ATP synthase
(ATPB).
The MS data presented above suggested that E. coli ATP synthase was present
in the high MW fraction of our DJ-1 preparation. To obtain additional evidence in
support of this idea, we examined the fractions obtained by sucrose-gradient
sedimentation of our DJ-1 preparation via Western blotting. The primary
antibodies used in this analysis were specific for human DJ-1 or the E. coli F1
ATP synthase beta subunit (ATPB). The results showed that ATPB (50 kDa) was
present primarily in the 15% sucrose gradient fractions, but also in the 50%
sucrose fractions and to a lesser extent in the 20% and 30% sucrose fractions
(Fig 3.9). These results confirm that ATPB is indeed present in the high MW
fraction of our DJ-1 preparation, mostly in an unassembled state detected in the
15% sucrose fraction but also in a higher-MW state (presumably as part of
assembled F1 ATP synthase) detected in the 50% sucrose fraction [202].
3.3.7 The ATPase activity in the high-MW fraction of our DJ-1
preparation is inhibited by sodium azide and piceatannol.
Sodium azide and piceatannol are two known classical F 1 ATPase inhibitors
[203]. To address whether the ATPase activity in our DJ-1 preparation could be
associated with assembled F1 ATPase, we tested whether the ATPase activity
was sensitive to either sodium azide or piceatannol. A preparation of
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recombinant DJ-1 was analyzed for ATPase activity with or without sodium azide
(1 mM and 5 mM) in the PNP assay, or in the absence or presence of
piceatannol in the MG assay. The results showed that sodium azide and
piceatannol both abolished the ATPase activity (Fig.3.10 and Fig 3.11). These
results suggest that the ATPase activity in our DJ-1 preparation could originate
from assembled F1 ATPase.
3.3.8 Evidence of a potential interaction between DJ-1 and E coli F1
ATP synthase.
The next sets of experiments were designed to test the hypothesis that DJ-1
interacts with F1 ATP synthase. To address this hypothesis, the supernatant
fraction of our DJ-1 preparation (obtained after ultracentrifugation in the absence
of sucrose to remove the high-MW species) was incubated with or without
purified bacterial F1 ATPase (obtained from Dr. Ahmad Zulfiqar, Kirksville College
of Osteopathic Medicine, MO). The incubation mix was fractionated by sucrose
gradient sedimentation. The sucrose gradient fractions were analyzed via
Western blotting using primary antibodies specific for DJ-1 and the E. coli F1 ATP
synthase beta subunit. The results showed that DJ-1 sediments to fractions with
a higher percentage of sucrose after incubation with F 1 ATPase, as evidenced by
the presence of DJ-1 immunoreactive bands in lanes corresponding to the 3050 % sucrose fractions (Fig 3.12). In contrast, DJ-1 was not detected in the
same sucrose fractions obtained upon sedimentation of a sample of DJ-1
incubated without F1 ATP synthase (Fig 3.13). As expected, most of the E. coli
F1 ATP synthase sedimented to fractions with a high percentage of sucrose as
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inferred from the sedimentation of the E. coli F1 ATP synthase beta subunit.
Therefore, we conclude that homodimeric DJ-1 present in the supernatant
fraction might interact with E. coli F1 ATP synthase to form a high-MW complex.
3.3.9 DJ-1 in the high MW fraction has a low level of C106
oxidation.
Based on the results above, we investigated whether the oxidation of DJ-1
modulates the protein’s interaction with E coli F1 ATP synthase. To address this
hypothesis, DJ-1 (supernatant fraction) was incubated with E coli F1 ATP
synthase at room temperature, and the mixture was analyzed via sucrose
gradient sedimentation. Sucrose fractions were analyzed via Western blotting
using antibodies specific for the oxidized form of DJ-1 or total DJ-1. Our results
showed that DJ-1 (detected with a total DJ-1 antibody) incubated with E coli F1
ATP synthase sediments to higher sucrose fraction (Fig 3.14), while oxidized
DJ-1 (detected with an antibody specific for oxidized DJ-1) does not sediment to
higher fractions (Fig 3.15). These findings suggest that the oxidation state of DJ1 modulates its interaction with F1 ATPase, and that reduced DJ-1 more readily
interacts with E coli F1 ATPase.

3.4 Discussion
DJ-1 has been shown to be involved in many neuroprotective functions, but its
biochemical function still remains to be elucidated. In this chapter we described
evidence of a possible biochemical function of DJ-1 involving the protein’s
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interaction with E.coli F1 ATPase, a protein complex that is structurally and
functionally well conserved with F1 ATPase with eukaryotic mitochondria.
3.4.1 A High MW fraction of our DJ-1 preparation is DJ-1immunoreactive, has ATPase activity and contains ring-like
structures
Our results revealed that ATPase activity in our DJ-1 preparation was abolished
by filtration. Sucrose gradient sedimentation and Western blot analysis showed
the presence of high-MW species immunoreactive with DJ-1 antibody in our
preparations of recombinant, human WT DJ-1. In addition, we found that the
high-MW fraction had ATPase activity and contained ring-like structures that
were visible by EM. Previous studies revealed that DJ-1 functions as a molecular
chaperone [141, 142]. In addition the formation of

high molecular weight

structures by Prxs is modulated by oxidative stress, which can induce dramatic
changes in quaternary structure [194] [195]. Accordingly, we inferred as one
possibility that DJ-1 might form a high-MW species that functions as an ATPdependent molecular chaperone. However, two observations contradicted this
hypothesis: homodimeric DJ-1 fractions without the high-MW species (after
separation via sucrose gradient ultra-centrifugation, SEC, and filtration) did not
show any ATPase activity or form ring-like structures, even after incubation, and
the C106A mutation had no effect on ATPase activity (data not shown). For this
reason, we turned our attention to analyzing the interaction of DJ-1 with E. coli
proteins that might be responsible for the ATPase activity.

70
3.4.2 DJ-1 positive Interacts with E.coli F1 ATP synthase to form
high-MW species.
MS analysis of the high-MW fraction isolated by sucrose gradient centrifugation
revealed the presence of E. coli F1 ATP synthase subunits, which are known to
assemble into ring-like structures [204]. A previous proteomics study revealed
that DJ-1 interacts with the α- and β-subunits of F1 ATP synthase in a rat
mesencephalic cell line [205]. The fact that the high MW fraction hydrolyzes ATP
and GTP, but not CTP, TTP, or ADP, is consistent with the idea that the ATPase
activity in our DJ-1 preparation originates from assembled F1 ATP synthase
[206]. Moreover, the high-MW fraction exhibited ATPase activity that was
inhibited by sodium azide and piceatannol, two inhibitors of F1 ATP synthase. In
addition, we found that homodimeric DJ-1 sedimented to fractions with a higher
percentage of sucrose after incubation in the presence versus the absence of
E.coli F1 ATP synthase. Collectively, these results imply that DJ-1 interacts with
E. coli F1 ATP synthase. Importantly, this proposed interaction is specific to DJ-1
because a sample of GST purified using the same bacterial expression system
did not show any ATPase activity. Our findings suggest that DJ-1 may interact
with F1 ATP synthase because this interaction may be a key component of the
DJ-1 chaperone function. MS results suggested that recombinant human DJ-1
might interact with other bacterial proteins, including E. coli F0 ATP synthase.
Although our studies were carried out with E.coli F1 ATP synthase, we
would predict that DJ-1 might interact in a similar way with F1 ATP synthase from
eukaryotic mitochondria given that the bacterial and eukaryotic enzymes have a
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high degree of structural and functional similarity [207]. DJ-1 has been described
as an atypical Prx that scavenges hydrogen peroxide (H2O2) via oxidation of
Cys106 [190]. The interaction between DJ-1 and ATP synthase (if validated)
would represent a new development in our understanding of how the protein
modulates mitochondrial function.
3.4.3 Unoxidized DJ-1 is the form of the protein that apparently
interacts with E.coli F1 ATP synthase.
A previous study showed that under conditions of oxidative stress, cysteine 106
(Cys 106) of DJ-1 becomes oxidized to the sulfinic and sulfonic acids (Cys-SO2H
and Cys-SO3H, respectively) [208]. We found that oxidized DJ-1 does not readily
interact with F1 ATP synthase, suggesting that the interaction of DJ-1 with E.coli
F1 ATPase is modulated by C106 oxidation. This observation suggests (as one
possibility) that DJ-1 forms a disulfide bond with one of the F1 ATP synthase
subunits, a mechanism that has precedence in disulfide bond formation between
DJ-1 and Ask1 kinase [121]

3.5 Conclusion
The data outlined in this chapter suggest that recombinant human DJ-1 (and in
particular the reduced form of the protein) interacts with E. coli F1 ATP synthase,
thereby enhancing ATP synthase function (e.g. perhaps via a mechanism
involving DJ-1 chaperone activity). We expect that a similar interaction is likely to
exist between DJ-1 and eukaryotic F1 (or F0F1) ATP synthase. Such an
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interaction could play an important role in alleviating mitochondrial dysfunction
and the resulting oxidative stress in PD.
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Figure 3.1-A ATPase activity associated with purified DJ-1 is eliminated upon filtration.
A. WT DJ-1 was dialyzed against 50 mM Tris-HCl, 50 mM NaCl, 1 mM MgCl2, pH 7.5 . A portion
of the protein was filtered through a 100 kDa filter. Equal amounts (15 μg) of the filtered and
unfiltered proteins were used in the PNP assay. ATP hydrolysis was monitored by the enzymatic
conversion of 7-methylguanosine to 7-methylguanine, which has a lower quantum yield, via a
continuous fluorimetric assay in the absence or presence of 1 mM ATP. Excitation, 300 nm;
2
emission, 410 nm. B. Table showing the slope and R values for the best-fit curves through the
data. N=1
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Figure 3.1-C. ATPase activity associated with purified DJ-1 is absent in the filtrate.
Absolute slope values from panel B were plotted for each sample.
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Figure 3.2 ATPase activity associated with purified DJ-1 is absent in the homodimer fraction.
A. WT DJ-1 was dialyzed against 50 mM Tris-HCl, 50 mM NaCl, 1 mM MgCl2, pH 7.5. The protein was
loaded onto a Superdex column, S200 and elution peaks were collected by monitoring the ultraviolet
absorbance detector. Equal amounts of protein (15 μg) from the S200 column were used in the PNP
assay. ATP hydrolysis was monitored by the enzymatic conversion of 7-methylguanosine to 7methylguanine, which has a lower quantum yield, via a continuous fluorimetric assay in the absence or
presence of 1 mM ATP. Excitation, 300 nm; emission, 410 nm. B. Absolute slope values from panel A
were plotted for each analyzed sample. N=1
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Figure 3.3 WT DJ-1 forms high molecular weight species.
WT DJ-1 was ultracentrifuged at 47,000 rpm (100,000 xg) at 4ºC for 2 h. The supernatant (S/N)
was removed, and the pellet was resuspended in buffer. Equal amounts of protein (1 μg)
(including the uncentrifuged protein, ‘Uncentr’) were then analyzed via Western blotting using a
DJ-1 specific primary antibody (1:4000). N=2
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Figure 3.4 WT DJ-1 forms high molecular weight species.
DJ-1 high-MW species were separated via ultracentrifugation through a sucrose gradient (20-50%
w/v) at 40,000 rpm (274,000 x g) for 18 h at 4 ºC. Gradient fractions were collected and analyzed
by SDS-PAGE on a 4-20% gradient gel. The proteins were transferred to a PVDF membrane and
probed with an antibody specific for DJ-1. Asterisk indicates a band that could correspond to
homodimeric DJ-1 or GST DJ-1. N=3
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Figure 3.5 DJ-1 associated high molecular weight fractions have ATPase activity.
A. WT DJ-1 was dialyzed against 50 mM Tris-HCl, 50 mM NaCl, 1 mM MgCl2, pH 7.5. The protein was
ultracentrifuged at 47,000 rpm (100,000 xg) at 4ºC for 2 h. The supernatant (S/N) was removed, and the
pellet was resuspended in buffer. Equal amounts of protein (15 μg) (including the uncentrifuged protein,
‘Uncentr’) were used in the PNP assay. ATP hydrolysis was monitored by the enzymatic conversion of 7methylguanosine to 7-methylguanine, which has a lower quantum yield, via a continuous fluorimetric
assay in the absence or presence of 1 mM ATP. Excitation, 300 nm; emission, 410 nm. B. Absolute slope
values from panel A were plotted for each analyzed sample. N=2
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Figure 3.6 DJ-1 fractions with a high sucrose percentage had a high ATPase activity.

A. WT DJ-1 was dialyzed against 50 mM Tris-HCl, 50 mM NaCl, 1 mM MgCl2, pH 7.5. The protein sample was
loaded on a 5% sucrose (top most sucrose percentage layer), and ultracentrifugation was carried out at 40,000
rpm (274,000 xg) for 18 h at 4 ºC. Fractions of about 500 μL each were collected from the bottom of the tube.
Equal amounts of protein (15 μg) were used in the PNP assay. ATP hydrolysis was monitored by the enzymatic
conversion of 7-methylguanosine to 7-methylguanine, which has a lower quantum yield, via a continuous
fluorimetric assay in the absence or presence of 1 mM ATP. Excitation, 300 nm; emission, 410 nm. B. Absolute
slope values from panel A were plotted for each analyzed sample. N=2
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Figure 3.7 WT DJ-1 oligomer consists of ring-like structures.
Fractions collected from a sucrose gradient (Figure 3.6) (10 μL) were deposited on carbon-coated
copper grids and negatively stained using 2 % uranyl-acetate. The images were taken using an
electron microscope. Collaboration with Dr. Stanciu’s lab. Ring-like structures (arrow) were only
present in the 50% sucrose fraction. N=2
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A

B

Figure 3.8 GST lacks ATPase activity.
A. GST was dialyzed against 50 mM Tris-HCl, 50 mM NaCl, 1 mM MgCl2, pH 7.5. Equal amounts of
protein (15 μg) were used in the PNP assay. ATP hydrolysis was monitored by the enzymatic conversion
of 7-methylguanosine to 7-methylguanine, which has a lower quantum yield, via a continuous fluorimetric
assay in the absence or presence of 1 mM ATP. Excitation, 300 nm; emission, 410 nm. B. Absolute
slope values from panel A were plotted against each analyzed sample. N=1
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Figure 3.9 WT DJ-1 sucrose fractions are immunoreactive for the E.coli ATPB subunit.
WT DJ-1 was dialyzed and separated via ultracentrifugation through a sucrose gradient (5-50% w/v)
at 40,000 rpm (274,000 x g) for 18 h at 4 ºC. Gradient fractions were collected and analyzed by SDSPAGE on a 4-20% gradient gel. The proteins were transferred to a PVDF membrane and probed with
an antibody specific for DJ-1 (A) and E.coli ATPase beta subunit (ATPB) (B). N=2
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A

B

Figure 3.10 ATPase activity associated with purified DJ-1 is inhibited by sodium azide.
A. WT DJ-1 was dialyzed against 50 mM Tris-HCl, 50 mM NaCl, 1 mM MgCl2, pH 7.5. Equal amounts of
protein (15 μg) were used in the PNP assay. ATP hydrolysis was monitored by the enzymatic conversion
of 7-methylguanosine to 7-methylguanine, which has a lower quantum yield, via a continuous fluorimetric
assay in the absence or presence of 1 mM ATP with 1 mM and 5 mM sodium azide. Excitation, 300 nm;
emission, 410 nm, B. Absolute slope values from panel A were plotted against each analyzed sample.
N=1
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Figure 3.11 ATPase activity associated with purified DJ-1 is inhibited by piceatannol. WT DJ-1 protein (1
μg) was incubated in the presence of 1 mM ATP, with or without 20 μM piceatannol, for 2 h at 37 ºC. Hydrolysis
of ATP was monitored using a malachite green assay designed to monitor the formation of a green
molybdophosphoric acid complex, which reports on the free organic phosphate concentration. The values were
obtained by reading the absorbance at 620 nm. N=1

85

A
75
50

ATPB

37
25
20

DJ-1

15

50%

30%

20%

15%

5%

Sucrose gradient

B

Figure 3.12 WT DJ-1 sediments to the 30-50% sucrose fractions after incubation with F1 ATPase.

A. WT DJ-1 (supernatant) was incubated with E.coli F1 ATPase at room temperature for 1 h. The complex formed
was separated via ultracentrifugation using a sucrose gradient (5%-50% w/v) at 40,000 rpm (274,000 x g) for 16 h at
4 ºC. Gradient fractions were collected and analyzed by SDS-PAGE on a 4-20% gradient gel. The proteins were
transferred to a PVDF membrane and probed with an antibody specific for DJ-1 and E.coli ATPase beta subunit
(ATPB). B. Quantification of the relative DJ-1 band intensities in different percentages of sucrose using Image J.
N=1
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Figure 3.13 WT DJ-1 sediments to the 15% sucrose fractions without incubation with F1 ATPase.

A. WT DJ-1 (supernatant) was incubated without E.coli F1 ATPase at room temperature for 1 h. The sample
was separated via ultracentrifugation using a sucrose gradient (5%-50% w/v) at 40,000 rpm (274,000 x g) for
16 h at 4 ºC. Gradient fractions were collected and analyzed by SDS-PAGE on a 4-20% gradient gel. The
proteins were transferred to a PVDF membrane and probed with an antibody specific for DJ-1. B.
Quantification of the relative DJ-1 band intensities in different percentages of sucrose using Image J. N=2

87

A
DJ-1

50%

30%

20%

15%

5%

Sucrose gradient

B

Figure 3.14 Unoxidized DJ-1 sediments with F1 ATP synthase to higher sucrose fractions.
A. WT DJ-1 (supernatant) was incubated without E.coli F1 ATP synthase at room temperature for 1 h. The
sample was separated via ultracentrifugation using a sucrose gradient (5%-50% w/v) at 40,000 rpm (274,000
x g) for 16 h at 4 ºC. Gradient fractions were collected and analyzed by SDS-PAGE on a 4-20% gradient gel.
The proteins were transferred to a PVDF membrane and probed with an antibody specific for DJ-1
(unoxidized). B. Quantification of the relative DJ-1 band intensities in different percentages of sucrose using
Image J. N=1
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Figure 3.15 Oxidized DJ-1 does not sediment with F1 ATPase to higher sucrose fractions.
A. WT DJ-1 supernatant was incubated without E. coli F1 ATPase at room temperature for 1 h. The sample was
separated via ultracentrifugation using a sucrose gradient (5%-50% w/v) at 40,000 rpm (274,000 x g) for 18 h at 4
ºC. Gradient fractions were collected and analyzed by SDS-PAGE on a 4-20% gradient gel. The proteins were
transferred to a PVDF membrane and probed with an antibody specific for oxidized DJ-1. B. Quantification of the
relative DJ-1 band intensities in different percentages of sucrose using Image J. N=1
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Table 3.1 Proteomic analysis of DJ-1 high–MW species.
Recombinant human WT DJ-1 sucrose fractions enriched with high-MW species were trypsinized to
generate peptides for mass spectrometry analysis. The table lists protein identified in the E.coli database
Description

Score

Coverage

#

#

Proteins

Peptides

Magnesium-transporting ATPase, P-type 1

360.80

47.55

1

46

ATP synthase subunit alpha

327.88

74.07

1

34

ATP synthase subunit beta

284.89

93.91

1

36

ATP-dependent zinc metalloprotease FtsH

271.81

59.01

1

34

ATP-dependent protease ATPase subunit HslU

223.17

58.92

1

27

ATP-dependent Clp protease ATP-binding subunit ClpX

187.67

74.76

1

26

ATP-binding component of serine protease

120.06

30.34

1

21

Uncharacterized ABC transporter ATP-binding protein yjjK

114.09

56.94

1

24

Lead, cadmium, zinc and mercury-transporting ATPase

105.42

36.20

1

19

ATP-dependent RNA helicase RhlB

104.31

54.63

1

20

ATP synthase subunit b

102.74

55.77

1

16

Oligopeptide transport ATP-binding protein oppD

90.14

51.63

1

13

ATP synthase gamma chain OS

79.60

60.98

1

15

ATP-binding component of transport system for maltose

70.79

50.94

1

16

ATP-independent RNA helicase dbpA

65.04

31.95

1

9

Oligopeptide transport ATP-binding protein oppF

61.99

41.32

1

13

ATP synthase subunit delta

52.95

52.54

1

7

Putative ATP-binding component of a transport system

46.84

65.80

1

9

Putative ATP-binding component of a transport system

45.41

45.23

1

8

ATP-dependent RNA helicase hrpA

40.58

9.92

1

10

ATP-binding component of high-

37.80

46.69

1

8

ATP-binding component of a membrane

34.28

42.79

1

6

Holliday junction ATP-dependent DNA helicase RuvB

33.30

34.23

1

7
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Glutamine transport ATP-binding protein glnQ

30.50

33.75

1

6

Uncharacterized ABC transporter ATP-binding protein ydcT

27.07

23.44

1

5

Lipoprotein-releasing system ATP-binding protein lolD

24.52

26.18

1

4

Spermidine/putrescine import ATP-binding protein potA

23.89

26.46

1

6

ATP-binding/permease protein cydC

18.59

12.91

1

5

ATP-binding component of 3rd arginine transport system

18.46

33.06

1

4

Uncharacterized ABC transporter ATP-binding protein

15.34

9.74

1

2

Dipeptide transport ATP-binding protein dppF

14.15

11.68

1

3

ATP-dependent transporter sufC

13.45

22.18

1

4

Uncharacterized ABC transporter ATP-binding protein yejF

13.44

5.10

1

2

Methionine import ATP-binding protein metN

12.52

13.70

1

2

Uncharacterized GTP-binding protein yjiA

11.54

11.64

1

3

ATP-binding/permease protein cydD

10.52

6.80

1

2
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CHAPTER 4: INTERPLAY OF DJ-1 AND ATP13A2 IN AUTOPHAGY

4.1. Introduction
The localization of ATP13A2 to lysosomal membranes may play a key role in
modulating autophagy. A loss of ATP13A2 function has been shown to
compromise

lysosomal

acidification,

decrease

proteolytic

processing

of

lysosomal enzymes, and reduce the degradation of lysosomal substrates [175].
Because dysfunctional mitochondria are degraded via autophagy [144],
impairment of autophagy resulting from ATP13A2 depletion is thought to trigger a
buildup of defective mitochondria that produce increased ROS [144, 176].
Expression of ATP13A2 protects mammalian cells from oxidative stress and
dysfunctional mitochondria [177]. In addition, loss of ATP13A2 function in human
fibroblasts triggers decreased ATP production, mitochondrial genome integrity,
and increased oxygen consumption and mitochondrial fragmentation [178].
Loss or mutation of mitochondrial DJ-1 induces an increase in ROS levels, a
decrease in respiration rates and mitochondrial membrane potential (MMP), and
a disruption of the critical balance between mitochondrial fusion and fission
dynamics [144, 190, 209]. Oxidative stress in M17 human neuroblastoma cells
results

in
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DJ-1 re-localization to mitochondria, a phenomenon associated with protection
against cytotoxicity [118]. DJ-1 has also been shown to protect neurons from
rotenone-induced oxidative stress and cell death [155, 156].
Aggregated aSyn is eliminated from cells via lysosomal autophagy [164, 175]. In
addition, aSyn accumulation induces a buildup of ROS which have been shown
to disrupt lysosomal membrane integrity, ultimately causing cell death [210, 211].
Furthermore, methamphetamine (METH), an addictive drug that elicits a PD-like
neurodegenerative phenotype in the brains of abusers, induces oxidative stress
and a build-up of autophagic vacuoles (autophagosomes) in neuronal cell lines
[212, 213]. DJ-1 is known to inhibit aSyn aggregation and toxicity, suppress
oxidative stress, and stimulate lysosomal autophagy [144, 156, 214].
The above sections highlight advances in our understanding of DJ-1 and
ATP13A2 neuroprotective activities. However, whether DJ-1 and ATP13A2
interact on a functional level to modulate mitochondrial and lysosomal function is
not known. We hypothesized that knockdown of DJ-1 or ATP13A2 would disrupt
lysosomal autophagy by causing a buildup of ROS that permeabilize lysosomal
membranes. Defects in lysosomal autophagy were characterized by monitoring
effects of DJ-1 and ATP13A2 knockdown on autophagosome accumulation in
cells cultured in the absence and presence of METH.
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4.2. Materials and Methods.
4.2.1 Materials
The bicinchoninic acid (BCA) protein assay kit was obtained from Pierce
Biotechnology
(Rockford, IL). The ECF substrate was purchased from GE Healthcare
(Piscataway, NJ). Coomassie Brilliant blue R250 and SDS were obtained from
Amresco (Solon, OH). Trizma base, 2-mercapto ethanol (2ME), ammonium
persulfate (APS), glycine, urea, iadoacetamide, sucrose, paraformaldehyde
(PFA), protease inhibitor cocktail, trypsin and ammonium chloride (NH4Cl) were
purchased from Sigma-Aldrich (St. Louis, MO). DTT was purchased from Gold
Biotechnology, fetal bovine serum (FBS), penicillin-streptomycin, Lipofectamine
2000, Opti-MEM, Trypsin-EDTA were obtained from Invitrogen (Carlsbad, CA).
4.2.2 Antibodies
The following antibodies were used in these studies: mouse anti human DJ-1
(clone 3E8) (Enzo Life Sciences, Farmingdale, NY), secondary anti mouse IgG
conjugated with alkaline phosphatase (Promega, Madison, WI, USA), secondary
anti rabbit IgG conjugated with alkaline phosphatase (Promega, Madison, WI,
USA). Anti ATP13A2 (Novus Biologicals, Littleton, CO, catalogue # NB11041486).
4.2.3 Preparation of lentiviral and adenoviral constructs
A lentiviral construct encoding a short hairpin RNAs (shRNAs) was used to
down-regulate rat DJ-1. An shRNA-encoding cassette spanning amino acid
residues 20–26 of rat DJ-1 [215] was ligated into the entry vector
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pENTR/U6(Invitrogen) and subsequently transferred to the lentiviral vector
pLenti6/BLOCK-iT DEST (Invitrogen) by recombination [126]. Plasmids encoding
human shRNA DJ-1 (clone 4918) and human shRNA ATP13A2 (clone BC
030267) were obtained from Dr. Benjamin Dehay (University of Bordeaux). A
lentiviral construct encoding rat shRNA ATP13A2 (Open Bio system, Clone ID
TRCN0000101716) was used to knockdown ATP13A2 protein in N27 cells. A
non-mammalian shRNA was used as a control plasmid DNA (Sigma Aldrich, Cat.
SHC002). A cDNA encoding ATP13A2 (clone BC 030267) obtained from Dr.
Susan Lindquist was ligated into pENTR/U6 and subsequently transferred to the
adenoviral vector pAd/CMV/V5-DEST (Invitrogen) by recombination [216].
4.2.4 Generation of N27 and SH-SY5Y stable cell lines with
ATP13A2 or DJ-1 knockdown
N27 rat dopaminergic neuronal cells were plated in the wells of a 6 well plate
(70,000 cells per well) in RPMI 1640 media with 15% (v/v) FBS and 1% (v/v)
penicillin-streptomycin (Pen-Strep). The cells were transduced with lentivirus
encoding rat shRNA ATP13A2 (MOI 5)

or rat shRNA DJ-1 (MOI 50)

An

additional set of cells was transduced with non-mammalian targeting shRNA
virus to generate a negative-control stable cell line. After 24-48 h, the media
containing the virus was replaced with media containing puromycin, a
mammalian selection marker (final concentration of 2 μg/mL), to select for cells
that were transduced by the lentivirus. Media with puromycin was replaced with
fresh media every 2 days for the first week to remove the dead cells, and
thereafter media was replaced with fresh media every 3 days. Individual colonies
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started forming on the plate after about 4-6 weeks. Each colony was carefully
selected using a glass colony ring, to which a layer of grease was applied on the
edge facing the plate surface to facilitate attachment of the ring to the plate. The
colonies were propagated in media containing puromcyin (2 μg/mL), and an
aliquot of the cells was frozen and stored in a liquid nitrogen tank.
SH-SY5Y human neuroblastoma cells were plated in the wells of a 6 well plate
(100,000 cells per well) in RPMI 1640 media with 15% (v/v) FBS and 1% (v/v)
Pen-Strep. The cells were transfected with a plasmid encoding human shRNA
DJ-1 and human shRNA ATP13A2 in the presence of Lipofectamine 2000 for 24
h at 37 ºC. Media containing the transfection reagent was replaced with RPMI
media without Pen-Strep for 24 h, to allow the cells to recover. The media was
then replaced with media with Pen-Strep and puromycin (2 μg/mL). The media
was replaced with fresh media every 2-3 days for about 4-6 weeks, and colonies
were selected and propagated as described above for the generation of N27
stably transduced cell lines. Additional sets of cells were transfected with a
scrambled human shRNA DJ-1 construct or a scrambled human shRNA
ATP13A2 construct to generate negative-control stable cell lines.
4.2.5 Acridine Orange (AO) labeling
To visualize acidic vesicles (e.g. autophagosomes) and lysosomes, cells were
incubated for 10 min at 37 ºC in an atmosphere containing 5 % (v/v) CO 2 in RPMI
1640 media supplement with AO (1 μg/mL), a lysosomotropic metachromatic
fluorochrome that emits an intense orange fluorescence after accumulating in
lysosomes and other acidic vesicles or organelles [161]. The media was replaced
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with phenol-red free media, and the cells were imaged on a confocal microscope
at 60x magnification (Nikon TE2000-U inverted fluorescence microscope, Nikon
Instruments, Melville, NY). A decrease in AO fluorescence intensity was
interpreted to mean an increase in lysosomal membrane permeability (LMP) or
the permeability of acidic vesicles, suggesting that membrane disruption had
occurred.
4.2.6 Western blotting
Cells were treated with NH4Cl (25 mM) for 4 h (in the case of an 8 h METH
incubation, NH4Cl was included during the final 4 h). Cells were dislodged from
the plate by pipetting, collected by centrifugation, washed with phosphatebuffered saline (PBS)(136 mM NaCl, 0.268 mM KCl, 10 mM Na 2HPO4, 1.76 mM
KH2PO4, pH 7.4), and lysed in RIPA buffer (25 mM Tris–HCl, pH 7.4, 150 mM
NaCl, 1 mM EDTA, 1% (v/v) Triton X-100, 0.1% (w/v) SDS, 1% (w/v) sodium
deoxycholate,

protease

inhibitor

cocktail(Sigma),

and

1

mM

phenylmethanesulfonylfluoride (PMSF)). After centrifugation at 13,000 g, the
detergent-soluble

(supernatant)

fraction

was

recovered.

The

protein

concentration in the soluble fraction was measured using the BCA Protein Assay
Kit (Pierce Biotechnology, Rockford, IL, USA), and equal amounts of protein
were separated via SDS–PAGE on a 4–20% (w/v) polyacrylamide gel. The
proteins were transferred to a 0.2 μm or 0.45 μm PVDF membrane, which was
probed

with a monoclonal antibody specific for mammalian aSyn (Syn-1,

1:1000), DJ-1 (1:250,000), ATP13A2 (1:2000). The secondary antibody was an
anti-rabbit IgG or an anti-mouse IgG conjugated to alkaline phosphatase (AP).
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Chemifluorescence images were obtained and analyzed using a Typhoon
imaging system (GE Health Sciences, Piscataway, NJ, USA). To confirm that
equal amounts of protein were loaded in all lanes, the blots were reprobed with a
primary antibody specific for β-actin (1:50000).
4.2.7. O2 Consumption
O2 consumption was monitored as described [217]. Stably transduced N27 cells
were plated in a 10 cm dish. The cells were harvested via centrifugation at 700 x
g (10 min, 4 ºC) and resuspended in O2 consumption buffer (20 mM HEPES, pH
7.2). Cellular respiration was measured using a Clark-type oxygen electrode
attached to a voltmeter (Digital Model 10 Controller, Rank Brothers, Ltd,
Cambridge, UK). The electrode was allowed to stabilize at 37 °C for 30 min to
ensure air saturation. To normalize the background current, the voltmeter was
set to zero using a polarizing voltage of 0.40 V. An aliquot of 1 x 106 cells (400
μL) was loaded into the respiration chamber, where the sensitivity control was set
to 1 V. This reflected 100% of the O2 concentration (0.21 mM) in the air-saturated
reaction medium present before the start of respiration [217]. The sample was
constantly stirred at 840 rpm using a magnetic stir bar located inside the
chamber. Using the Pico Technology software program (PicoTechnology, Ltd.,
Cambridgeshire, UK), the O2 level remaining in the chamber at any time during
respiration was automatically logged (with 10 sec intervals) as a voltage (Vo2).
The Vo2 reflected the voltage generated by the reaction of O2 with the electrode
(Vo2 steadily decreased as O2 was consumed) [217]. Percentage O2 response
versus time was plotted.
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4.2.8 Fluorescence microscopy using tandem GFP-RFP-LC3
construct.
GFP-RFP-LC3 stable cell lines were generated by Dr. Amy Griggs. In brief, SHSY5Y human neuroblastoma cells were plated in the wells of a 6 well plate
(100,000 cells per well) in RPMI 1640 media with 15% (v/v) FBS and 1% (v/v)
Pen-Strep. The cells were transfected with a plasmid encoding GFP-RFP-LC3 in
the presence of Lipofectamine 2000 for 6 h at 37 ºC. Media containing the
transfection reagent was replaced with RPMI media without Pen-Strep for 24 h,
to allow the cells to recover. The media was then replaced with media with PenStrep and G418 (600 μg/mL). The media was replaced with fresh media every 23 days for about 4-6 weeks, and colonies were selected and propagated as
described in section 4.2.4 above.
The cells were transduced with adenoviruses encoding WT ATP13A2 or the
control protein LacZ (MOI of each virus = 50). After 48 h, the cells were
incubated with METH (200 μM) for 24 h. The cells were fixed with 4% w/v
paraformaldehyde (PFA) and imaged using a confocal microscope (excitation
wavelengths, 488 and 594 nm; emission wavelengths, 525 and 617 nm
respectively). The tandem LC3 construct was used to monitor autophagic flux
based on a difference in the pH stability of GFP versus RFP [218]. The acidic pH
in

autolysosomes

(cellular

structures

resulting

from

the

fusion

of

autophagosomes with lysosomes) quenches the GFP fluorescence signal,
whereas the RFP fluorescence signal is preserved under acidic conditions [218].
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4.2.9 RNA isolation and qRT-PCR
Cells were harvested by centrifugation at 1300 x g for 10 min at 4 ºC. mRNA was
extracted using the E.Z.N.A total RNA kit I (Omega Bio-Tek). Total RNA (200 ng)
was reverse-transcribed by the iScript Select cDNA Synthesis Kit (170–8896)
(Bio-Rad).

Quantitative PCR (qRT-PCR) was performed using the iQ SYBR

Green PCR Kit (Bio-Rad) using forward and reverse primers specific for
ATP13A2, DJ-1, or the control GAPDH. ATP13A2, DJ-1 and GAPDH levels were
normalized and fold change was calculated using the following formula:

2''Ct

^( Ct ,TG Ct ,CG ) KD ( Ct ,TG Ct ,CG )control `

2

Where Ct,TG represents the crossing threshold for the target gene, Ct,CG
represents the crossing threshold for the target gene, ‘KD’ refers to mRNA
obtained from ATP13A2 or DJ-1 knockdown cells, and ‘control’ refers to mRNA
obtained from cells transduced with a control (non-targeting) vector.
4.3. Results
4.3.1 Decreased levels of DJ-1 and ATP13A2 mRNA and protein in
N27 stable knockdown cells.
To generate N27 rat dopaminergic neuronal cells with a stable knockdown of DJ1 or ATP13A2, the cells were transduced with lentivirus encoding shRNA DJ-1 or
shRNA ATP13A2. Additional cells were transduced with lentivirus encoding nonmammalian targeting shRNA to generate a control stable cell line. Analysis of the
N27 shRNA DJ-1 cell lysates by qRT-PCR and Western blotting revealed an
80% decrease in DJ-1 mRNA levels (Fig 4.1A) and a corresponding 60%
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knockdown in DJ-1 protein levels (Fig 4.1B, C) compared to the control
knockdown stables. Analysis of lysates from two clonal lines of N27 shRNA
ATP13A2 (‘colony 10’ and ‘colony 12’) by qRT-PCR and Western blotting
revealed a 90% decrease in the level of ATP13A2 mRNA (colony 10 line) (Fig
4.2A) and a complete loss of ATP13A2 protein in both clonal lines (predicted
molecular weight, 129 kDa) (Fig 4.2B). Furthermore, we generated both DJ-1
and

ATP13A2

knockdown

stables

in

SH-SY5Y

human

dopaminergic

neuroblastoma cells (data not shown).
4.3.2 N27 ATP13A2 knockdown cells show an increase in LC3 II
levels.
Previous studies have reported that cells depleted of ATP13A2 via RNAimediated knockdown exhibit decreased proteolytic processing of lysosomal
enzymes, reduced degradation of lysosomal substrates, increased mitochondrial
mass, and increased ROS production [175, 176]. Based on these studies, we
tested the effect of our generated N27 ATP13A2 knockdown cells on lysosomal
degradation. We hypothesized that knockdown of ATP13A2 should increase the
accumulation of autophagosomes. To address this hypothesis, N27 ATP13A2
knockdown cells (colony 10 and colony 12) and control (non-targeting) stable
cells were treated with or without METH in the absence or presence of NH4Cl, an
inhibitor of autophagosome degradation by lysosomes. METH induces oxidative
stress and a build-up of autophagic vacuoles (autophagosomes) in neuronal cell
lines [212, 213]. Autophagosomes levels were monitored by measuring levels of
an autophagic marker, LC3 II, via Western blotting.

The results showed an
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increased level of LC3 II in lysates from colony 10 cells (Fig 4.3) and colony 12
cells (Fig 4.4) compared to control cells, in the absence or presence of METH
(the effect was more pronounced in cells co-treated with METH). For both
ATP13A2 knockdown clonal cell lines treated with METH, the magnitude of the
increase in LC3 II levels was dependent on the time of METH treatment (4 h
versus 8 h). Similar effects of ATP13A2 knockdown and METH treatment on
LC3 levels were obtained with ATP13A2 knockdown cells cultured in the
presence of NH4Cl, except that the LC3 levels in these cell lysates were
markedly greater. These results suggest that ATP13A2 knockdown in N27 cells
induces an increase in autophagosome formation and/or disrupts the lysosomal
degradation pathway, thereby triggering autophagosome accumulation. In
addition, METH sensitizes the cells to the effects of ATP13A2 knockdown,
causing further increases in LC3-II autophagosome levels.
4.3.3 ATP13A2 overexpression enhances autophagosome
clearance.
We hypothesized that overexpression of ATP13A2 would enhance the clearance
of autophagosomes. To address this hypothesis we overexpressed ATP13A2 or
the control protein LacZ from adenoviral constructs in cells stably expressing a
‘tandem’, GFP-RFP-LC3 construct that enables one to monitor autophagic flux
based on the fact that GFP and RFP can both be visualized in autophagosomes,
whereas GFP (but not RFP) is destabilized (and thus not visible by microscopy)
in more acidic compartments such as autolysosomes. The results show that
overexpression of ATP13A2 (but not the control protein LacZ) decreases the

102
number of autophagosomes and autolysosomes in METH-treated cells (Fig. 4.5).
These data suggest that ATP13A2 may enhance autophagosome clearance
(thus inhibiting autophagosome accumulation) in METH-treated cells, potentially
by enhancing autophagosome-lysosome fusion and/or lysosomal function [175].
4.3.4 ATP13A2 knockdown reduces the METH-induced upregulation of acidic cellular compartments.
A loss of ATP13A2 function has been shown to compromise lysosomal
acidification [175]. Accordingly, we hypothesized that the knockdown of ATP13A2
would disrupt lysosomal pH in our cell culture models. To address this
hypothesis, N27 ATP13A2 knockdown cells were treated with or without METH,
and levels of lysosomes and acidic organelles (e.g. autophagosomes) were
monitored using AO, a lysosomotropic metachromatic fluorochrome that emits an
intense red fluorescence after accumulating in acidic cellular compartments. Our
results showed that METH induced an increase in AO-positive cellular structures
in control N27 cells expressing a non-targeting shRNA, whereas this effect was
suppressed in ATP13A2 knockdown cells (Fig 4.6). These results suggest that
ATP13A2-deficient N27 cells show a decrease in METH-induced accumulation of
AO-positive structures, perhaps because of a defect in the acidification of cellular
compartments on the autophagic or endocytic pathway.
4.3.5 ATP13A2 knockdown increases levels of mitochondrial
protein carbonyls.
The next experiment was designed to determine the effect of ATP13A2
knockdown on mitochondrial oxidative stress. We hypothesized that ATP13A2
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would increase levels of mitochondrial protein carbonyls, a marker of
mitochondrial

oxidative

stress.

To

address

this

hypothesis,

MES23.5

dopaminergic neuronal cells were transduced with lentivirus encoding shRNA
ATP13A2. Mitochondrial fractions were isolated and analyzed for protein
carbonyls The results showed that cells depleted of ATP13A2 have elevated
levels of mitochondrial protein carbonyls compared to control (untransduced)
cells (Fig 4.7). These results suggest that shRNA ATP13A2 sensitizes
mitochondrial proteins to oxidation, potentially by triggering increases in
mitochondrial ROS.
4.3.6 N27 DJ-1 knockdown cells show an increase in LC3-II levels.
Cells lacking DJ-1 exhibit a decrease in mitochondrial degradation, an increase
in mitochondrial mass, and an increase in ROS levels [144]. Other studies have
shown that DJ-1 suppresses the formation of protein carbonyls in rat primary
midbrain cultures [126]. ROS accumulation may cause lysosomal membrane
permeability

(LMP),

Accordingly,

we

thus

disrupting

hypothesized

that

lysosomal
DJ-1

degradation

knockdown

would

pathways.
cause

an

accumulation of autophagic vesicles in neuronal cells. To address this
hypothesis, N27 DJ-1 knockdown cells and cells stably transduced with a control
(non-targeting shRNA) vector (section 4.3.1) were treated with or without METH,
in the absence or presence of NH4Cl. Autophagosome levels were monitored by
determining the cellular content of the autophagic marker, LC3-II. Our results
showed that knockdown of DJ-1 in N27 cells increased levels of LC3-II compared
to control cells, in the absence or presence of METH (the effect was more
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pronounced in cells co-treated with METH) (Fig. 4.8). Similar effects of DJ-1
knockdown and METH treatment on LC3 levels were obtained with DJ-1
knockdown cells cultured in the presence of NH4Cl, except that the LC3 levels in
these cell lysates were markedly greater. These results suggest that DJ-1
knockdown in N27 cells induces an increase in autophagosome formation and/or
disrupts the lysosomal degradation pathway, thereby triggering autophagosome
accumulation. In addition, METH sensitizes the cells causing a further increase in
autophagosome levels.
4.3.7 N27 cells depleted of ATP13A2 or DJ-1 show a decrease in
O2 consumption.
Impairment of autophagy resulting from ATP13A2 depletion is thought to trigger a
buildup of defective mitochondria that produce increased ROS [144, 176]. On the
other hand, DJ-1 dysfunction induces an increase in ROS levels, a decrease in
respiration rates and mitochondrial membrane potential (MMP), and a disruption
of the critical balance between mitochondrial fusion and fission dynamics [144].
Based on these studies, we hypothesized that knockdown of either ATP13A2 or
DJ-1 in N27 cells would disrupt mitochondrial function, hence decreasing the rate
of O2 consumption. To address this hypothesis, N27 cells depleted of ATP13A2
or DJ-1 were characterized in terms of their rates of cellular respiration using a
Clark-type oxygen electrode attached to a voltmeter. The results revealed that
cells depleted of ATP13A2 or DJ-1 showed a decreased rate of O2 consumption
compared to control cells transduced with a non-targeting shRNA vector (Fig.
4.9). Taken together, these results suggest that a loss of ATP13A2 or DJ-1
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function results in a disruption of mitochondrial respiration as evident in the
observed decrease in O2 consumption.
4.3.8 DJ-1 depletion via shRNA knockdown results in downregulation of ATP13A2 expression in N27 cells, and vice-versa.
Depletion of ATP13A2 or DJ-1 in N27 cells leads to the same biological outcome
namely, an increase in LC3-II accumulation (Fig 4.3, Fig 4.4 and Fig 4.8).
Accordingly, we hypothesized that the two proteins might interact on a functional
level to modulate mitochondrial or/and lysosomal function. As one approach to
address this hypothesis, we investigated whether the expression levels of
ATP13A2 and DJ-1 are co-regulated by examining the effects of depleting each
protein via shRNA-mediated knockdown on the expression level of the other.
Levels of ATP13A2 mRNA and protein were examined in N27 DJ-1 knockdown
cells via qRT-PCR and Western blotting, respectively, whereas DJ-1 mRNA
levels were examined in N27 ATP13A2 knockdown cells via qRT-PCR. N27 DJ1 knockdown cells showed a 90% decrease in ATP13A2 mRNA (Fig. 4.10A) and
a 90% decrease in ATP13A2 protein (Fig 4.10B) relative to control cells
transduced with a non-targeting shRNA vector. Levels of DJ-1 mRNA in N27
ATP13A2 knockdown cells were decreased by 35-40% relative to control cells
(Fig. 4.11). These results are the first to suggest that DJ-1 and ATP13A2 are coregulated in N27 cells.
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4.3.9 DJ-1 is down-regulated in primary midbrain cultures depleted
of ATP13A2, whereas ATP13A2 is up-regulated in midbrain
cultures depleted of DJ-1.
Additional experiments were carried out to determine whether ATP13A2 and DJ1 are co-regulated in rat primary midbrain cultures. On the basis of results
obtained with N27 knockdown cells (4.3.8), we hypothesized that midbrain
cultures depleted of DJ-1 would exhibit a decrease in ATP13A2 expression
levels, and vice versa. To address this hypothesis, primary mid brain cultures
transduced with lentivirus encoding a DJ-1 shRNA or an ATP13A2 shRNA were
analyzed by qRT-PCR to determine levels of ATP13A2 and DJ-1 mRNAs. The
results showed an approximately 72% decrease in DJ-1 mRNA levels in cultures
depleted of ATP13A2 (70% knockdown of ATP13A2 mRNA) compared to control
cultures (Fig 4.12). Surprisingly, we observed a 70% increase in ATP13A2
mRNA levels in cultures depleted of DJ-1 (72% knockdown of DJ-1 mRNA)
compared to control cultures (Fig 4.13).

Collectively, these data provide

evidence that DJ-1 and ATP13A2 are co-regulated in rat primary midbrain
cultures.

4.4. Discussion
4.4.1 Knockdown of ATP13A2 causes LC3-II accumulation.
A loss of ATP13A2 function causes impaired lysosomal acidification [175].
Autophagosomes fuse with lysosomes to degrade or recycle their components.
An optimal lysosomal pH among other factors is important for this fusion event.
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Disruption of this process leads to an accumulation of autophagosomes. Our
data showed an increase in LC3-II levels in N27 ATP13A2 knockdown cells, and
this effect was enhanced in the presence of METH. These results suggest, as
one possibility, that ATP13A2 knockdown elicits an increase in lysosomal pH,
resulting

in

inhibition

of

autophagosome-lysosome

fusion

and

thus

autophagosome accumulation, as evident by increased LC3-II levels. Additional
results revealed a time-dependent increase in LC3-II levels in N27 ATP13A2
knockdown cells and control cells cultured in the presence versus the absence of
METH. METH has been shown to induce oxidative stress by increasing the levels
of ROS in striatal, mesencephalic and cortical astrocytes [219]. Furthermore,
METH induces neurotoxicity in dopamine neurons by disrupting dopamine
sequestration in synaptic vesicles leading to oxyradical stress, autophagy and
neurite degeneration [220]. In addition, impairment of autophagy resulting from
ATP13A2 depletion is thought to trigger a buildup of defective mitochondria that
produce increased ROS [144, 176]. ROS causes lysosomal membrane
permeability (LMP), disrupting lysosomal function [221]. Therefore, we infer that
METH-induced accumulation of autophagosomes may reflect up-regulation of
autophagy and/or a disruption of autophagosome-lysosome fusion, and both
effects could be enhanced by ATP13A2 depletion. ATP13A2 dysfunction could
lead to induction of autophagy based on NH4Cl results (NH4Cl combined with
ATP13A2 KD gives much higher LC3-II levels than NH4Cl in control cells). This
could be an indirect effect of oxidative stress leading to proteasome inhibition
and as a result induction of autophagy [222, 223].
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4.4.2 ATP13A2 overexpression enhances lysosomal clearance in
SH-SY5Y cells.
ATP13A2 overexpression has been shown to rescue zinc toxicity and promote
mitochondrial fusion in human olfactory neurosphere cultures [183]. Additional
evidence suggests that ATP13A2 enhances autophagic flux and inhibit
autophagosome accumulation, potentially by enhancing lysosomal function
and/or autophagosome-lysosome fusion [175]. Here, we showed using SH-SY5Y
cells expressing a tandem GFP-RFP-LC3 construct that METH induced an
increase in the relative number of puncta that emitted red and green
fluorescence (corresponding to autophagosomes) or only red fluorescence
(corresponding to autolysosomes), and this effect was diminished in cells
overexpressing ATP13A2. These results suggest that overexpression of
ATP13A2 enhances autophagosome clearance, perhaps via a mechanism
involving

enhanced

lysosome

acidification

resulting

in

increased

autophagosome-lysosome fusion and/or lysosomal degradation. It is also
possible that ATP13A2 over-expression results in a decrease in METH-induced
autophagosome formation via an indirect mechanism involving alleviation of
oxidative stress.
4.4.3 Knockdown of ATP13A2 disrupts autophagy and lysosomal
pH.
The results of AO staining experiments showed a METH-dependent increase in
the relative number of red puncta corresponding to acidic vesicles or organelles
in control N27 cells, whereas this increase was abolished in N27 ATP13A2
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knockdown cells. Examples of cellular structures that could take up the AO stain
include autophagosomes [224], macropinosomes [225], or lysosomes. Our
results suggest that there is a decrease in the acidification of these structures in
cells depleted of ATP13A2. A disruption of lysosomal pH would be predicted to
cause an accumulation of autophagosomes, and thus the AO staining data are
consistent with data showing that LC3-II-positive vesicles accumulate in
ATP13A2 knockdown cells (see above).
4.4.4 ATP13A2 knockdown increases levels of protein carbonyls in
ME23.5 cells.
Impairment of autophagy resulting from ATP13A2 depletion is thought to trigger a
buildup of defective mitochondria that produce increased ROS [144, 176]. Here
we showed that knockdown of ATP13A2 in MES23.5 cells increased the level of
mitochondrial protein carbonyls, an indicator of oxidative stress. Based on the
data presented here (see above) and by other groups [175] that ATP13A2 is
involved in lysosomal autophagy, we infer that the increase in the levels of
mitochondrial protein carbonyls in ATP13A2 knockdown cells reflects a buildup of
dysfunctional mitochondria. Normally, dysfunctional mitochondria would be
degraded via mitophagy, a process involving mitochondrial uptake by a
phagophore that develops into an autophagosome which in turn fuses with a
lysosome. Impairment of lysosome acidification is expected to lead to an
accumulation of autophagosomes and a buildup of dysfunctional mitochondria
that trigger ROS accumulation. ROS-mediated LMP completes a vicious cycle of
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lysosomal impairment, disruption of mitophagy, accumulation of dysfunctional
mitochondria, and oxidative stress.
4.4.5 Knockdown of DJ-1 disrupts lysosomal function thus
increasing autophagosome accumulation.
Loss or mutation of mitochondrial DJ-1 induces an increase in ROS levels, a
decrease in respiration rates and mitochondrial membrane potential (MMP), and
a disruption of the critical balance between mitochondrial fusion and fission
dynamics [144]. Knockdown of DJ-1 in both N27 cells and SH-SY5Y cells
increased levels of autophagosomes as evident from Western blotting data
showing an increase in cellular LC3-II content. An increase in LC3-II content
might

be

due

to

disrupted

lysosomal

function,

leading

to

inefficient

autophagosome elimination via the lysosomal degradation pathway. The
increase in LC3-II levels was enhanced in N27 cells depleted of DJ-1 upon
treatment of the cells with METH. We attribute this outcome to a disruption of
autophagosome-lysosome fusion caused by ROS-induced LMP, a phenomenon
that could result from oxidative stress associated with DJ-1 knockdown and
METH exposure [161].

We can also infer that DJ-1 contributes to the up-

regulation of autophagy triggered by METH, perhaps as a cellular defense
mechanism involving Erk-dependent signaling [144]. In addition, we infer that
METH-induced accumulation of autophagosomes may reflect METH-induced upregulation of autophagy and/or a disruption of autophagosome-lysosome fusion.
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4.4.6 N27 cells depleted of ATP13A2 or DJ-1 exhibit decreased
rates of cellular respiration.
N27 cells stably transduced with an shRNA construct targeting ATP13A2 or DJ-1
showed a decrease in O2 consumption compared to control cells. In contrast,
human mutant ATP13A2 fibroblasts showed an increase in O 2 consumption
compared to control fibroblasts [178]. A key difference between N27 cells and
fibroblasts is that only the N27 cells produce dopamine. Cytosolic dopamine
undergoes auto-oxidation to form dopamine o-quinone, a process that leads to a
buildup of ROS [18]. In turn, dopamine o-quinone forms adducts with Parkin (a
protein involved in mitochondrial quality control) [226] and subunits of
mitochondrial complex I [40, 227]. Therefore, we infer (as one possibility) that
the decrease in O2 consumption in N27 cells depleted of ATP13A2 could be due
to a buildup of mitochondria that have become dysfunctional (at least in part) via
a mechanism involving damage to mitochondrial proteins by dopamine oquinone. In contrast, the increase in O2 consumption in ATP13A2 mutant
fibroblasts presumably reflects a compensatory response to a reduction in ATP
levels in these cells [178].
4.4.7 ATP13A2 and DJ-1 show evidence of co-regulated
expression.
Our findings from studies of N27 cells depleted of ATP13A2 and DJ-1 suggest
that the two proteins may share a common (or partially overlapping)
neuroprotective pathway. Consistent with this idea, data obtained by qRT-PCR
revealed that the level of ATP13A2 mRNA was decreased in N27 DJ-1
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knockdown cells, and vice versa. Similarly, there was a decrease in DJ-1 mRNA
levels in primary midbrain cultures depleted of ATP13A2 by shRNA-mediated
knockdown. These results, the first to show that ATP13A2 and DJ-1 are coregulated, suggest that expression of the genes encoding the two proteins might
be modulated by a common transcription factor that binds to shared promoter
motifs. Contrarily, we found that ATP13A2 mRNA increased in primary midbrain
cultures depleted of DJ-1 by shRNA-mediated knockdown. These results suggest
that the gene expression patterns of ATP13A2 and DJ-1 in N27 cells versus
primary midbrain cultures are overlapping but non-identical, perhaps reflecting
differences in N27 gene expression patterns associated with immortalization
and/or the fact that primary midbrain cultures consist of a mixture of glial and
neuronal cell types. The fact that ATP13A2 expression is increased in primary
midbrain cultures implies that ATP13A2 up-regulation may have evolved as a
protective mechanism to alleviate toxic effects of DJ-1 down-regulation (e.g.
oxidative stress, disrupted autophagy) in neuronal and/or glial cells. Further
studies are needed to address whether DJ-1 over-expression can rescue cellular
dysfunction associated with ATP13A2 knockdown, and vice versa.

4.5 Conclusion
The data outlined in this chapter suggest that ATP13A2 and DJ-1 both regulate
lysosomal autophagy. Knockdown of either protein increased LC3-II levels,
suggesting an accumulation of autophagosomes. Furthermore, we showed that
METH induced further increases in LC3-II levels in cells depleted of ATP13A2 or
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DJ-1. This effect can be attributed to increases in ROS that could in turn trigger
LMP, thereby disrupting lysosomal-autophagosome fusion. Finally, gene
expression data suggest that (i) ATP13A2 and DJ-1 are co-regulated in N27
cells, and (ii) neurotoxic effects of DJ-1 depletion may be rescued by ATP13A2
up-regulation in primary midbrain cultures. These findings are important because
they shed light on the role of lysosomal autophagy in ATP13A2- and DJ-1mediated protection against neurotoxicity elicited by METH. In addition they
provide insight into the biochemical mechanism by which DJ-1 preserves
mitochondrial function in neurons exposed to PD-related insults, and they
highlight the interplay between DJ-1 and ATP13A2 in regulating lysosomal
degradation.
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Figure 4.1 Levels of DJ-1 mRNA and protein in N27 stable knockdown cells.
A. qRT-PCR data showing reduced DJ-1 mRNA levels in N27 DJ-1 knockdown cells versus control cells.
B. N27 cells were stably transduced with a lentivirus encoding an shRNA specific for DJ-1 or a control
shRNA that does not target any mammalian genes. Lysates from control and DJ-1 knockdown cells (one
clonal line of each) were analyzed via Western blotting (30 μg of protein per lane) using primary antibodies
specific for DJ-1 and beta-actin. C. Bar graph showing DJ-1 band intensities normalized to the β-actin
signal. N=2
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Figure 4.2 Levels of ATP13A2 mRNA and protein in N27 stable knockdown cells.
A. qRT-PCR data showing reduced ATP13A2 mRNA levels in N27 ATP13A2 knockdown cells (colony
10) versus control cells. B. N27 cells were stably transduced with a lentivirus encoding an shRNA
specific for ATP13A2 or a control shRNA that does not target any mammalian genes. (“Ctrl”). Lysates
from control cells (one clonal line) and ATP13A2 knockdown cells (two clonal lines: colony 10 [col 10]
and colony 12 [col 12]) were analyzed via Western blotting (30 μg of protein per lane) using primary
antibodies specific for ATP13A2 and beta-actin. N=2.
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Figure 4.3 ATP13A2 knockdown in N27 cells (colony 10) induces up-regulation of the autophagy
marker, LC3-II.

(A) N27 ATP13A2 knockdown cells (colony 10, ‘Col 10’) and control cells transduced with a non-targeting
shRNA vector were cultured in the absence or presence of METH for 4 h or 8 h. Cell lysates were analyzed via
Western blotting (30 μg of protein per lane) using primary antibodies specific for LC3 and beta-actin. (B) Bar
graph showing LC3-II band intensities normalized to the β-actin signal (relative to a value of 1 for ‘control
untreated’). N=2
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Figure 4.4 ATP13A2 knockdown in N27 cells (colony 12) induces up-regulation of the autophagy
marker, LC3-II.
(A) N27 ATP13A2 knockdown cells (colony 12, ‘Col 12’) and control cells transduced with a non-targeting
shRNA vector were cultured in the absence or presence of METH for 4 h or 8 h. Cell lysates were
analyzed via Western blotting (30 μg of protein per lane) using primary antibodies specific for LC3 and
beta-actin. (B) Bar graph showing LC3-II band intensities normalized to the β-actin signal (relative to a
value of 1 for ‘control untreated’). N=1
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Figure 4.5 METH-induced autophagosome accumulation is suppressed in SH-SY5Y cells expressing
ATP13A2.
SH-SY5Y cells stably expressing a ‘tandem’ GFP-RFP-LC3 construct were untreated (A); treated with METH
(200 μM) for 24 h (B); or transduced with adenovirus encoding LacZ (C) or ATP13A2 (D) (MOI of each virus
= 50) for 48 h before being treated with METH for 24 h. The cells were imaged by fluorescence microscopy.
Puncta that emit GFP and RFP fluorescence are thought to correspond to autophagosomes, whereas puncta
that emit RFP (but not GFP) fluorescence likely correspond to autolysosomes. N=1

119

A

B
Control No METH

ATP13A2 KD No METH

Control + 200 μM METH

ATP13A2 KD + 200 μM METH

Figure 4.6 ATP13A2 is involved in the METH-induced accumulation of acidic vesicles or organelles.
A. Images showing different levels of red puncta corresponding to acidic vesicles or organelles in N27 ATP13A2
knockdown cells and in control cells transduced with a non-targeting shRNA vector. The cells were treated with or
without METH (200 μM, 8 h) and subsequently incubated with acridine orange (AO) (1 μg/mL, 10 min), a
fluorescent dye that emits red fluorescence when taken up by acidic vesicles or organelles Live cells were
imaged in phenol red-free media by fluorescence microscopy. B. Bar graph showing relative numbers of acidic
vesicles or organelles in N27 ATP13A2 knockdown cells or control cells treated as described in panel A. For each
set of cells, regions of interest were drawn around invidual red puncta and scored for mean fluorescence intensity.
The data are presented as the percentage of puncta with a mean intensity greater than a threshold value, defined
as the average mean intensity plus two standards deviations for untreated control cells. N=1
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Figure 4.7 Knockdown of ATP13A2 triggers an increase in the oxidation of mitochondrial
proteins.
(A) MES23.5 cells were transduced with shPark9 lentivirus (MOI 50). Mitochondrial fractions were
isolated after 72 h and analyzed for protein carbonyl levels using the OxyBlot kit (Millipore). The image
shows the resulting Western blot (9 μg of protein per lane) probed with an antibody specific for 2,4
dinitrophenylhydrazone (DNP). (B) Bar graph showing protein carbonyl band intensities normalized to
the β-actin signal (relative to a value of 1 for control cells). N=1
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Figure 4.8 DJ-1 knockdown in N27 cells induces up-regulation of the autophagy marker,
LC3-II.
(A) N27 DJ-1 knockdown cells and control cells transduced with a non-targeting shRNA vector were
cultured in the absence or presence of METH for 4 h or 8 h. Cell lysates were analyzed via Western
blotting (30 μg of protein per lane) using primary antibodies specific for LC3 and beta-actin. (B) Bar
graph showing LC3-II band intensities normalized to the β-actin signal (relative to a value of 1 for
‘control untreated’). N=2
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Figure 4.9 N27 cells depleted of DJ-1 or ATP13A2 have reduced rates of O2 consumption.
N27 cells stably transduced with a lentiviral construct encoding an shRNA specific for ATP13A2 or DJ-1,
and control cells transduced with a non-targeting shRNA vector, were analyzed for O2 consumption rates
using a Clark-type oxygen electrode attached to a voltmeter. N=2
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Figure 4.10 ATP13A2 mRNA and protein levels are decreased in N27 cells depleted of DJ-1.
(A) Bar graph showing ATP13A2 mRNA levels determined via qRT-PCR in N27 DJ-1 knockdown
cells and in control cells (relative to a value of 1 for control cells). (B) Lysates from N27 DJ-1
knockdown cells and control cells transduced with a non-targeting shRNA vector were analyzed via
Western blotting (30 μg of protein per lane) using primary antibodies specific for ATP13A2 and
beta-actin. N=1
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Figure 4.11 DJ-1 mRNA levels are decreased in N27 cells depleted of ATP13A2.
The bar graph shows DJ-1 mRNA levels determined via qRT-PCR in N27 ATP13A2
knockdown cells and in control cells (relative to a value of 1 for control cells). N=1
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Figure 4.12 DJ-1 mRNA levels are decreased in rat primary midbrain cultures depleted of
ATP13A2.

The bar graph shows DJ-1 mRNA levels determined via qRT-PCR in primary midbrain cultures
transduced with lentivirus encoding a control (non-targeting) shRNA or an shRNA specific for DJ-1 or
ATP13A2 (relative to a value of 1 for control cells). N=1
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Figure 4.13 ATP13A2 mRNA levels are increased in rat primary midbrain cultures depleted of DJ-1.
The bar graph shows ATP13A2 mRNA levels determined via qRT-PCR in primary midbrain cultures
transduced with lentivirus encoding a control (non-targeting) shRNA or an shRNA specific for DJ-1 or
ATP13A2 (relative to a value of 1 for control cells). N=1
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CHAPTER 5: DISCUSSION

5.1. Summary of our research
The monomeric subunit of DJ-1 is highly homologous to the Pyrococcus
horikoshii 1704 gene product (PH1704), a bacterial cysteine protease which
forms a hexamer. DJ-1 has an additional α helix (helix H8) at the C-terminus
compared to PH1704. A recent study has shown that a truncated form of DJ-1
(15 amino acids cleaved at the C terminus, resulting in the removal of helix H8)
has much greater protease activity compared to full length DJ-1 [46]. This Cterminally truncated form of DJ-1 (DJ-1Δ15) was found to accumulate in
dopaminergic cells exposed to oxidative stress, leading Chen et al. [46] to
conclude that full-length WT DJ-1 is in fact a zymogen that becomes activated
via a redox-sensitive cleavage mechanism. Importantly, however, it is not known
whether DJ-1Δ15 has the ability to form a hexamer, or whether such a hexameric
structure is responsible for the observed protease activity. Based on the
structural similarity of DJ-1Δ15 and PH1704, we proposed in Chapter 2 that DJ1Δ15 can form functional hexamers as a result of removal of the C-terminal 15
residues, and this oligomerization could allow for the formation of a new interface
necessary for the assembly of a trimer of dimers. In contrast, full length DJ-1
does not form a hexamer because helix H8 occludes this interface. To address
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this hypothesis, we purified DJ-1Δ15 from an E.coli expression system. The
protein was analyzed via a native PAGE and AUC, and a predicted threedimensional structure of DJ-1Δ15 was examined using PyMOL. Our results
showed that DJ-1Δ15 can potentially form high order oligomeric species.
Specifically, the results of our Pymol analysis revealed that DJ-1Δ15 has the
ability to form a closed hexamer by forming a new interface (patch 1’). In
contrast, full-length DJ-1 cannot adopt a hexameric structure due to steric
conflicts involving helix 8, as expected. Formation of the DJ-1Δ15 hexamer
brings a glutamate residue at position 84 in proximity to the catalytic site to
potentially form a catalytic triad with residues C106 and H126. In addition, the
results of AUC analyses revealed that the formation of high-order oligomeric
species by DJ-1Δ15 is concentration-dependent.
Oxidative stress can cause mitochondrial dysfunction through S-glutathionylation
of mitochondrial proteins, including F0F1 ATP synthase, thus decreasing their
activity [228]. Furthermore, glutathione-S-transferases (GSTs) have been shown
to protect cells against oxidative stress [229]. In Chapter 3 we reported that high
molecular weight (high-MW) species immunoreactive with a DJ-1 antibody are
present in our preparations of recombinant, human WT DJ-1 (purified initially as
a GST fusion protein prior to removal of the GST tag via proteolytic cleavage).
These high-MW species have ATPase activity and appear as ring-like structures
when examined by electron microscopy. In contrast, purified GST lacks both
ATPase activity and ring-like structures. Interestingly, a proteomics study
revealed that DJ-1 interacts with the α- and β-subunits of F1 ATP synthase in a
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rat mesencephalic cell line [205]. The biochemical function of DJ-1 is unknown.
Our results show that DJ-1 interacts with E.coli F1 ATP synthase, and that the
reduced form of DJ-1 is preferentially involved in this interaction. These results
provide new insights into the biochemical mechanism by which DJ-1 preserves
mitochondrial function in neurons exposed to PD-related insults – namely, by
interacting with F1 ATPase, a protein complex that is structurally and functionally
well conserved between E. coli and eukaryotic mitochondria.
ATP13A2 knockdown has been shown to decrease proteolytic processing of
lysosomal enzymes, reduce degradation of lysosomal substrates, increase
mitochondrial mass, and increase ROS production [175, 176]. Cells lacking DJ-1
exhibit a decrease in mitochondrial clearance (mitophagy), an increase in
mitochondrial mass and an increase in ROS levels [144]. In Chapter 4, we
examined the functional interplay between ATP13A2 and DJ-1 in neuronal cells
exposed to a PD-related stress, METH, a drug that imposes a burden on the
autophagy clearance system in dopaminergic neuronal cells [230, 231]. We
hypothesized that knockdown of ATP13A2 or DJ-1 in N27 dopaminergic cells
would disrupt lysosomal degradation, leading to an increase in LC3-II, an
autophagosome marker. Our results showed that ATP13A2 knockdown in N27
cells led to an increase in LC3-II. This increase was further enhanced with the
addition of METH in the absence or presence of NH4Cl, an agent that disrupts
lysosomal pH. Because ATP13A2 is a lysosomal ATPase that is known to acidify
lysosomes [175], our data suggest that the increase in LC3-II-positive
autophagosomes may be due to the disruption of lysosomal pH, a defect that
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precludes autophagosome-lysosome fusion [232]. Furthermore, N27 cells
depleted of ATP13A2 showed a decrease in red puncta staining using AO, a dye
that accumulates in acidic vesicles (pH<4). In addition, overexpression of
ATP13A2 interfered with the METH-induced up-regulation of autophagosomes
and autolysosomes in SH-SY5Y dopaminergic neuronal cells. These results
suggest that ATP13A2 may enhance autophagic clearance and inhibit
autophagosome accumulation in METH-treated cells, potentially by enhancing
autophagosome-lysosome fusion and/or lysosomal degradation [175]. Likewise,
N27 DJ-1 knockdown cells exhibited increased levels of LC3-II. Previous results
have shown that cells lacking DJ-1 exhibit a decrease in mitochondrial clearance,
an increase in mitochondrial mass, and an increase in ROS levels [144]. ROS
accumulation could disrupt the lysosomal membrane [161]. Therefore, our data
suggest that N27 DJ-1 knockdown cells have high basal levels of ROS that
cause disruption of the lysosomal membrane and hence prevent the fusion of
autophagosomes with lysosomes. METH may enhance this disruption of
autophagy by triggering additional oxidative stress. In addition, DJ-1 might be
enhancing clearance of the autophagosomes.
To analyze the effects of DJ-1 or ATP13A2 knockdown on mitochondrial
respiration, the rate of O2 consumption was measured on in intact cells. Our
results showed a decrease in O2 consumption for N27 cells depleted of either
ATP13A2 or DJ-1. Dopaminergic neurons contain high levels of ROS due to the
presence of dopamine. Dopamine undergoes auto-oxidation to the o-quinone
form, a reaction that involves the generation of superoxide radicals [36]. Because
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dopaminergic neurons have higher basal levels of oxidative stress than other
types of neurons, they are more susceptible to pathogenic mechanisms that
further up-regulate ROS, including mitochondrial dysfunction. Interestingly,
another group reported that fibroblasts from human patients with an ATP13A2
mutation exhibit increased O2 consumption rates compared to control fibroblasts.
These data suggest that dopamine auto-oxidation may render dopaminergic
neuronal cells more vulnerable to a build-up of dysfunctional mitochondria as a
result of a loss of ATP13A2 or DJ-1 function. Dopamine auto-oxidation should
result in the formation of o-quinones that disrupt complex 1 in dopaminergic
neuronal cells, and this effect could be enhanced by the accumulation of
dysfunctional mitochondria as a result of mitophagy impairment in cells depleted
of ATP13A2 or DJ-1. In additional experiments, we sought to determine whether
ATP13A2 and DJ-1 interact on a functional level to modulate mitochondrial
or/and lysosomal function. We found that ATP13A2 mRNA and protein were
down-regulated in N27 DJ-1 knockdown cells, and levels of DJ-1 mRNA were
reduced in N27 ATP13A2 knockdown cells. These results suggest that DJ-1 and
ATP13A2 are co-regulated in N27 cells. In contrast, ATP13A2 mRNA was
increased in rat primary midbrain cultures depleted of DJ-1 via shRNA
knockdown. These results suggest that the gene expression patterns of
ATP13A2 and DJ-1 in N27 cells versus primary midbrain cultures are overlapping
but non-identical, perhaps reflecting differences in N27 gene expression patterns
associated with immortalization and/or the fact that primary midbrain cultures
consist of a mixture of glial and neuronal cell types. Up-regulation of ATP13A2 in
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primary midbrain cultures implies that ATP13A2 may have evolved as a
protective mechanism to alleviate toxic effects of DJ-1 down-regulation (e.g.
oxidative stress, disrupted autophagy) in neuronal and/or glial cells.
5.2. Future directions
5.2.1 To determine whether E84A is a member of a catalytic triad in
hexameric DJ-1Δ15.
In Chapter 2, we reported that hexamer formation by DJ-1Δ15 might bring a
glutamate residue 84 from one subunit (E84) into a position suitable for forming a
catalytic triad with cysteine 106 (C106) and histidine 126 (H126) form a second
subunit. Formation of the catalytic triad could be essential for the ability of DJ1Δ15 to function as a protease. To determine whether E84 is important for the
protease activity of DJ-1Δ15, we have generated a construct with E84 mutated to
alanine (DJ-1Δ15-E84A). Future experiments will be aimed at examining the
protease activity of this mutant. If E84A shows a loss of protease activity, then
we will infer that DJ-1-Δ15 adopts a hexameric structure to enable the assembly
of a catalytic triad essential for protease function, similar to PH1704 [112]. If our
prediction is incorrect, then we will infer that the formation of a catalytic triad
involving E84 is not essential for the protease activity of DJ-1-Δ15. A potential
limitation is that DJ-1-Δ15 may fail to form a stable hexamer as a result of C106
over-oxidation. In this case, we will repeat the experiment with DJ-1Δ15-C106A
and/or DJ-1Δ15-C106D. The findings from this study will provide more insights
into how DJ-1Δ15 carriers out a protease function by revealing information about
its active site architecture, how it is regulated, and its optimal substrates.
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Ultimately it may be possible to develop inhibitors to test the biological role of this
protease.
5.2.2 To determine whether GST modulates interactions of DJ-1
with F1 ATP synthase.
In Chapter 3, we determined that recombinant; human WT DJ-1 (purified initially
as a GST fusion protein prior to removal of the GST tag via proteolytic cleavage)
contained high molecular weight (high-MW) species immunoreactive with DJ-1
antibodies. The presence of these high-MW species correlates with (i) the
presence of ring-like structures that can be visualized by TEM, and (ii) the
presence of ATPase activity in our DJ-1 preparations. We inferred that the highMW species observed in these preparations consisted of a complex of DJ-1 with
F1 ATP synthase. In contrast, untagged recombinant human WT DJ-1 purified via
ion-exchange chromatography did not contain high-MW, DJ-1-immunoreactive
species or show ATPase activity (data not shown). Based on these results, a
future goal will be to determine the role of GST in modulating the interaction
between DJ-1 and F1 ATP synthase.
To assess whether DJ-1 interacts with GST, a pull-down experiment will
be carried out by incubating recombinant untagged DJ-1 with GST bound to a
resin with covalently linked glutathione (GSH). The protein material isolated using
the pull-down approach will be analyzed via Western blotting using antibodies
specific to DJ-1 and GST. To examine whether GST co-purifies with DJ-1 and/or
F1 ATP synthase, GST and untagged DJ-1 will be co-expressed in E.coli cells
and purified using a GSH resin. The purified protein will be tested for ATPase

134
activity and for the presence of F1 ATP synthase subunits, GST, and DJ-1 via
Western blotting. Evidence of ATPase activity and of ATP synthase subunits,
GST, and DJ-1 in the affinity-purified protein would suggest that DJ-1 and F1 ATP
synthase form a complex with GST. To further address this hypothesis, the
purified protein will be analyzed via mass spectrometry. Previous studies have
shown that in the presence of oxidative stress, F1 ATP synthase subunits are
glutathionylated, thus decreasing their activity [228]. In addition, cysteine
oxidative post-translational modifications (for example, disulfide bond formation
within) the ATP synthase complex cause conformational changes that modulate
its activity [233]. Furthermore, Drosophila glutathione S-transferase Omega 1
(GSTO) rescued glutathionylated ATP synthase beta subunit, thus enhancing its
activity [229]. Glutathionylation, deglutathionylation and other post translational
modifications of mitochondrial ATP synthase subunits are important for these
proteins to function under oxidative stress conditions. Therefore, results from our
studies will shed more light on mechanism for DJ-1 neuroprotection in
mitochondria. First, DJ-1 may modulate ATP synthase activity by protecting
against glutathionylation through its interaction with ATP synthase, second, in the
presence of GST, DJ-1 may deglutathionylate ATP synthase subunits. Third,
GST may modulate the DJ-1-F1 ATP synthase interaction.
5.2.3 To determine the effects of aSyn on F1 ATPase activity.
A proteomics study revealed that aSyn interacts with the α- and β-subunits of F1
ATP synthase in a rat mesencephalic cell line [205]. To examine the effects of
aSyn on the function of F1 ATP synthase, purified F1 ATP synthase complex will
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be incubated in the absence or presence of aSyn and tested for ATPase activity.
If we find that aSyn inhibits the ATPase function, then the F 1 ATP synthase
complex will be pre-incubated with aSyn in the absence or presence of DJ-1 and
re-tested for ATPase activity. As a complementary approach, the effects of aSyn
on the ATPase activity associated with recombinant DJ-1 (purified as a GST
fusion protein prior to removal of the GST tag via proteolytic cleavage) will be
examined. These data will provide insight into how aSyn elicits mitochondrial
dysfunction and the mechanism by which DJ-1 carries out its neuroprotective
function.
5.2.4 To determine the effects of DJ-1 or ATP13A2 expression on
LC3-II accumulation and mitochondrial respiration.
Future efforts will be directed towards testing the effects of over-expressing DJ-1
or ATP13A2 in N27 cells depleted of either protein. We predict that DJ-1 or
ATP13A2 expression will rescue defects in autophagosome-lysosome fusion in
ATP13A2 or DJ-1 knockdown cells, respectively. We also predict that defects in
mitochondrial respiration will be rescued by over-expression of DJ-1 in ATP13A2
knockdown cells (and vice versa). If this is true, then we will infer that both
proteins act in concert to alleviate mitochondrial dysfunction and/or the
accumulation of defective mitochondria triggered by PD-related insults.
5.2.5 To determine the effects of DJ-1 or ATP13A2 expression on
aSyn stability.
Aggregated aSyn is eliminated from cells via lysosomal autophagy [164, 175]. In
addition, aSyn accumulation induces a buildup of ROS which have been shown
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to disrupt lysosomal membrane integrity, ultimately causing cell death [210, 234].
DJ-1 is known to inhibit aSyn aggregation and toxicity, suppress oxidative stress,
and stimulate lysosomal autophagy [144, 156, 214]. We predict that DJ-1 and
ATP13A2 interact functionally to inhibit aSyn aggregation and neurotoxicity. To
address this hypothesis, N27 cells depleted of ATP13A2 will be transduced with
an adenovirus encoding DJ-1, whereas DJ-1 knockdown cells will be transduced
with an adenovirus encoding ATP13A2 (both sets of cells will be co-transduced
with aSyn virus). As controls, cells depleted of ATP13A2 or DJ-1 will be
transduced with LacZ virus (instead of virus encoding DJ-1 or ATP13A2). The
effects of DJ-1 or ATP13A2 over-expression on aSyn stability, lysosomal
membrane integrity, and autophagosome accumulation will be evaluated. We
predict that DJ-1 or ATP13A2 over-expression will rescue defects in aSyn
stability, lysosomal membrane integrity, and autophagosome-lysosome fusion in
ATP13A2 or DJ-1 knockdown cells, respectively. If this is true, then we will infer
that DJ-1 and ATP13A2 act as part of a common pathway to preserve lysosomal
autophagy and ensure the lysosomal clearance of toxic aSyn aggregates (Fig.
5.1). Preliminary data from an experiment involving ATP13A2 knockdown in
dopaminergic neuronal cells suggest that ATP13A2 plays a role in modulating
aSyn accumulation (Fig. 5.2). Consistent with this finding, evidence suggests that
the C. elegans ATP13A2 ortholog inhibits the misfolding of human aSyn [179].
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5.2.6 To determine the effects of DJ-1 or ATP13A2 knockdown on
aSyn degradation.
We predict that DJ-1 and ATP13A2 cooperate to promote aSyn degradation. To
address this hypothesis, lysosomes will be isolated from N27 cells depleted of
ATP13A2 or DJ-1 via centrifugation of a mitochondrial-lysosomal fraction through
a discontinuous metrizamide density gradient [235]. Lysosomes will be incubated
with radiolabeled aSyn and glyceraldehyde 3-phosphate dehydrogenase
(GAPDH), a protein that will serve as a positive control [235]. After precipitating
the proteins with trichloroacetic acid, the degree of proteolysis will be calculated
as the percentage of the initial acid-insoluble radioactivity (protein) transformed
into acid-soluble radioactivity (amino acids and small peptides resulting from
protein degradation) [236]. The data will indicate whether lysosomes isolated
from cells depleted of ATP13A2 or DJ-1 have a reduced ability to degrade aSyn
in a cell-free system, which will serve as a model of chaperone-mediated
autophagy [237]. We predict that lysosomes isolated from cells depleted of
ATP13A2 may be dysfunctional as a result of acidification defects and thus may
exhibit a decreased rate of aSyn clearance via autophagy. In addition, we predict
that lysosomes isolated from cells depleted of DJ-1 may be damaged by
oxidative stress and thus may exhibit a decreased rate of aSyn degradation. If
these predictions are validated, then we will infer that the function of ATP13A2
and/or DJ-1 is necessary for aSyn degradation via lysosomal autophagy (i.e.
both chaperone-mediated autophagy and macroautophagy).
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In addition, the rates of aSyn degradation in N27 cells depleted of ATP13A2 or
DJ-1 or in control cells will be assessed via pulse pulse-chase analysis. The cells
will be labeled with
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S-methionine (pulse), washed with buffer, and incubated in

fresh media with excess unlabeled methionine (chase). The half-life of aSyn will
be estimated from exponential decay curves of radioactivity versus time.
Collectively, our findings may support a model in which ATP13A2 and DJ-1
protect against the neurotoxicity of PD-related insults by suppressing the
accumulation of dysfunctional mitochondria and ROS production, thereby
alleviating defects in lysosomal membrane integrity and autophagy (Fig 5.1)
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Mitochondrial
ATP synthase

?
?

Figure 5.1 Proposed model for DJ-1 and ATP13A2 neuroprotective interplay.
DJ-1 maintains lysosomal membrane integrity by inhibiting mitochondrial dysfunction and ROS
accumulation. Expression of ATP13A2 in the lysosomal membrane is predicted to be necessary for the
elimination of aSyn aggregates and dysfunctional mitochondria via autophagy. Cells deficient in DJ-1
and/or ATP13A2 will show an increase in ROS and a decreased rate of clearance of aSyn and
dysfunctional mitochondria.
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Figure 5.2 Knocking down ATP13A2 increases the accumulation of aSyn A53T in dopaminergic
cells.
MES 23.5 cells were transduced with A53T adenovirus +/- ATP13A2 shRNA lentivirus. The cells were
harvested after 96 h, and cell lysates were analyzed via Western blotting (15 μg of protein per lane) using
a primary antibody specific for aSyn (A, B) or ATP13A2 (C, D). Control MES 23.5 cells were untreated.
Beta-actin was used as a loading control.
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APPENDIX: LIST OF PRIMERS
Primers used to generate DJ-1Δ15 variants in Chapter 2 and Chapter 3
Human DJ-1 (Forward primer)
5’CGAGCTCTCTCTAGAAATAATTTTGTTTAACTTTAAGAAGGAGATATACATA
TG GCTTCCAAAAGAGCTCTGGT 3’
Human DJ-1Δ15 (Reverse primer)
5’ CGAGCTCTCCTCGAGCTAGCCATTCAGGGCTTCAACAATTG 3’
Primers used for qRT PCR in Chapter 4
Rat Park9 (Forward primer)
5’ GCGTACACAGGGCATCTT 3’
Rat Park9 (Reverse primer)
5’ GACCAGTGGCAGCAACAT 3’
Rat Park7 (Forward primer)
5' GGAGAACAGGAAGGGCCTCATA 3'
Rat Park7 (Reverse primer)
5' GGGTGCGATGTAACCTTGCAT 3'
Rat GAPDH (Forward primer)
5' GAACATCATCCCTGCATCCA 3'
Rat GAPDH (Reverse primer)
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5' CCAGTGAGCTTCCCGTTCA 3'
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